"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2021/194819 A1,154-530-532-888-593,2021-09-30,2021,US 2021/0022701 W,2021-03-17,US 202117181562 A;;US 202063000814 P,2020-03-27,DISPENSING UNIT HAVING FIXED FLEXIBLE DIAPHRAGM SEAL,A dispensing unit (40) of a dispensing system (10) configured to dispense viscous material on an electronic substrate includes a support housing (42) and a fluidic housing (44) supported by the support housing. The fluidic housing includes a chamber and an inlet configured to deliver viscous material to the chamber from a material feed tube. The dispensing unit further includes a nozzle assembly (46) releasably secured to the housing and configured to close an end of the fluidic housing. The dispensing unit further includes a reciprocating piston (62) disposed partially within the chamber of the fluidic housing. The piston is configured to dispense viscous material from the nozzle assembly. The dispensing unit further includes a fixed flexible diaphragm seal (70) configured to be secured to the fluidic housing and to the piston.,ILLINOIS TOOL WORKS,FORGET RONALD;;KARLINSKI THOMAS,,https://lens.org/154-530-532-888-593,Patent Application,yes,4,0,7,7,0,B05B1/3046;;B05C5/0225;;B05C11/1034;;B05C5/0216;;B05C11/1034;;B05C5/0225;;B05B1/3046;;B05C5/0216;;F16K41/04;;B05C11/1026;;F16K41/04;;B05C11/1026;;B05C5/0225;;B05B1/3046;;B05C5/0216,B05C5/02;;B05C11/10,,0,0,,,,PENDING
2,EP,A1,EP 4126394 A1,029-182-613-038-179,2023-02-08,2023,EP 21718684 A,2021-03-17,US 202063000814 P;;US 202117181562 A;;US 2021/0022701 W,2020-03-27,DISPENSING UNIT HAVING FIXED FLEXIBLE DIAPHRAGM SEAL,,ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J,,https://lens.org/029-182-613-038-179,Patent Application,yes,0,0,7,7,0,B05B1/3046;;B05C5/0225;;B05C11/1034;;B05C5/0216;;B05C11/1034;;B05C5/0225;;B05B1/3046;;B05C5/0216;;F16K41/04;;B05C11/1026;;F16K41/04;;B05C11/1026;;B05C5/0225;;B05B1/3046;;B05C5/0216,B05C5/02;;B05C11/10,,0,0,,,,PENDING
3,WO,A1,WO 2023/014424 A1,059-604-825-254-848,2023-02-09,2023,US 2022/0030908 W,2022-05-25,US 202117393003 A,2021-08-03,TILT AND ROTATE DISPENSER HAVING MATERIAL FLOW RATE CONTROL,"A dispensing system includes a frame, a support coupled to the frame, a dispensing unit configured to dispense viscous material, and a gantry assembly coupled to the frame. The gantry assembly includes a gantry configured to support the dispensing unit and to move the dispensing unit in x-axis, y-axis and z-axis directions and a tilt and rotate subassembly configured to tilt and rotate the dispensing unit. The dispensing system further includes a controller configured to control dispensing unit and the gantry assembly to perform a dispense operation on the electronic substrate. The controller is configured to control the dispensing unit to dispense material from the nozzle of the dispensing unit at a flow rate configured to deposit a desired amount or density of material on the electronic substrate along a three-dimensional path.",ILLINOIS TOOL WORKS,FORGET RONALD;;KARLINSKI THOMAS;;REID SCOTT,,https://lens.org/059-604-825-254-848,Patent Application,yes,3,0,4,4,0,H05K13/0469;;B05B13/0415;;B05C5/02;;B05C5/0216;;H01L21/6715,H05K13/04,,0,0,,,,PENDING
4,TW,A,TW 202202234 A,125-463-460-260-473,2022-01-16,2022,TW 110110787 A,2021-03-25,US 202063000814 P;;US 202117181562 A,2020-03-27,Dispensing unit having fixed flexible diaphragm seal,A dispensing unit of a dispensing system configured to dispense viscous material on an electronic substrate includes a support housing and a fluidic housing supported by the support housing. The fluidic housing includes a chamber and an inlet configured to deliver viscous material to the chamber from a material feed tube. The dispensing unit further includes a nozzle assembly releasably secured to the housing and configured to close an end of the fluidic housing. The dispensing unit further includes a reciprocating piston disposed partially within the chamber of the fluidic housing. The piston is configured to dispense viscous material from the nozzle assembly. The dispensing unit further includes a fixed flexible diaphragm seal configured to be secured to the fluidic housing and to the piston.,ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J,,https://lens.org/125-463-460-260-473,Patent of Addition,no,0,0,7,7,0,B05B1/3046;;B05C5/0225;;B05C11/1034;;B05C5/0216;;B05C11/1034;;B05C5/0225;;B05B1/3046;;B05C5/0216;;F16K41/04;;B05C11/1026;;F16K41/04;;B05C11/1026;;B05C5/0225;;B05B1/3046;;B05C5/0216,B05C5/02;;B05C11/10;;F16K41/04,,0,0,,,,PENDING
5,WO,A1,WO 2023/014422 A1,149-710-564-208-027,2023-02-09,2023,US 2022/0030890 W,2022-05-25,US 202117392998 A,2021-08-03,TILT AND ROTATE DISPENSER HAVING MOTION CONTROL,"A dispensing system includes a frame, a support coupled to the frame, a dispensing unit configured to dispense viscous material, and a gantry assembly coupled to the frame. The gantry assembly includes a gantry configured to support the dispensing unit and to move the dispensing unit in x-axis, y-axis and z-axis directions and a tilt and rotate subassembly configured to tilt and rotate the dispensing unit. The dispensing system further includes a controller configured to control dispensing unit and the gantry assembly to perform a dispense operation on the electronic substrate. The controller is configured to simultaneously coordinate the movement of the gantry assembly and the tilt and rotate subassembly to position and orient the nozzle of the dispensing unit a predetermined distance and orientation from the electronic substrate while dispensing material along a three-dimensional path.",ILLINOIS TOOL WORKS,FORGET RONALD;;KARLINSKI THOMAS;;REID SCOTT,,https://lens.org/149-710-564-208-027,Patent Application,yes,3,0,4,4,0,H05K13/0469;;H05K13/0815;;B05C5/0225;;B05C11/1015;;H05K13/0469;;H05K2203/0126,H05K13/04,,0,0,,,,PENDING
6,US,B2,US 8149414 B2,076-308-686-558-293,2012-04-03,2012,US 34522908 A,2008-12-29,FR 0709092 A,2007-12-26,Method and device for measuring the spectral phase or the combined spectral and spatial phases of ultra short light pulses,"The method and device for measuring the spectral phase or combined spectral and spatial phases of ultra short light pulses, consisting of a decomposition of the light pulse to be measured in two identical replicas called signal pulse and primary reference pulse, respectively, of different polarization or direction and the phase characteristics of which are essentially identical to the original pulse, a temporal filtering of the primary reference pulse by a nonlinear interaction generating a secondary reference pulse of average frequency essentially identical and of spectral width greater than the spectral width of the primary reference pulse, and a spectral interferometry measurement by recombination of this secondary reference pulse and the signal pulse with a given temporal offset.",KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS;;FASTLITE,KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS,FASTLITE (2008-10-13),https://lens.org/076-308-686-558-293,Granted Patent,yes,2,0,8,8,0,G01J11/00;;G01J11/00,G01B9/02,356/450;;356/451,3,2,156-510-756-511-650;;064-227-735-028-37X,10.1016/s1296-2147(01)01279-3;;18087344;;10.1364/ol.23.000792,"C. Dorrer, et al., ""Characterization of the spectral phase of ultrashort light pulses"", Comptes Rendus de l'Acadamie des Sciences, Series IV, Dec. 2001, p. 1415-1426, vol. 2, No. 10, Acadamie des sciences/Editions scientiques et medicales Elsevier SAS.;;C. Iaconis et al., ""Spectral phase interferometry for direct electric-field reconstruction of ultrashort optical pulses"", Optics Letters, vol. 23, No. 10, pp. 792-794, May 15, 1998.;;Y. R. Shen, ""The Principles of Nonlinear Optics: Equation 1.10"", John Wiley & Sons, Inc. (1984).",ACTIVE
7,FR,A1,FR 2925956 A1,141-797-904-340-774,2009-07-03,2009,FR 0709092 A,2007-12-26,FR 0709092 A,2007-12-26,PROCEDE ET DISPOSITIF POUR LA MESURE DE LA PHASE SPECTRALE OU DE PHASES SPECTRALE ET SPATIALE COMBINEES D'IMPULSIONS LUMINEUSES ULTRA BREVES.,"The method involves decomposing an ultra-brief light pulse (Ii) into pulses respectively denominating a signal pulse (Is) and a primary reference pulse (Irp), of different polarization or direction of propagation, where phase characteristics of the pulses are identical to the light pulse. Interaction is carried out between the primary pulse and a non-linear optical material (DMNL) to generate a secondary reference pulse (Irs). Spectral or spatial interferometric measurement is carried out by recombining the secondary pulse and the signal pulse with given or null time and angular offsets. An independent claim is also included for a device for measuring a spectral phase or combined spectral and spatial phase of an ultra-brief light pulse.",FASTLITE SARL,KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS,,https://lens.org/141-797-904-340-774,Patent Application,no,1,0,8,8,0,G01J11/00;;G01J11/00,G01J11/00;;G02F1/19,,1,1,156-510-756-511-650,10.1016/s1296-2147(01)01279-3,"DORRER C ET AL: ""Characterization of the spectral phase of ultrashort light pulses"", COMPTES RENDUS DE L'ACADEMIE DES SCIENCES, SERIE IV (PHYSIQUE, ASTROPHYSIQUE) EDITIONS ELSEVIER FRANCE, vol. 2, no. 10, December 2001 (2001-12-01), pages 1415 - 1426, XP002489017, ISSN: 1296-2147",INACTIVE
8,US,A1,US 2021/0301943 A1,165-614-507-196-533,2021-09-30,2021,US 202117181562 A,2021-02-22,US 202117181562 A;;US 202063000814 P,2020-03-27,DISPENSING UNIT HAVING FIXED FLEXIBLE DIAPHRAGM SEAL,A dispensing unit of a dispensing system configured to dispense viscous material on an electronic substrate includes a support housing and a fluidic housing supported by the support housing. The fluidic housing includes a chamber and an inlet configured to deliver viscous material to the chamber from a material feed tube. The dispensing unit further includes a nozzle assembly releasably secured to the housing and configured to close an end of the fluidic housing. The dispensing unit further includes a reciprocating piston disposed partially within the chamber of the fluidic housing. The piston is configured to dispense viscous material from the nozzle assembly. The dispensing unit further includes a fixed flexible diaphragm seal configured to be secured to the fluidic housing and to the piston.,ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J,ILLINOIS TOOL WORKS INC (2021-03-10),https://lens.org/165-614-507-196-533,Patent Application,yes,34,0,7,7,0,B05B1/3046;;B05C5/0225;;B05C11/1034;;B05C5/0216;;B05C11/1034;;B05C5/0225;;B05B1/3046;;B05C5/0216;;F16K41/04;;B05C11/1026;;F16K41/04;;B05C11/1026;;B05C5/0225;;B05B1/3046;;B05C5/0216,F16K41/04;;B05C5/02;;B05C11/10,,0,0,,,,DISCONTINUED
9,EP,B1,EP 2075556 B1,029-770-545-724-687,2010-01-27,2010,EP 08291179 A,2008-12-12,FR 0709092 A,2007-12-26,Method and device for measuring the spectral phase or the combined spectral and spatial phase of ultra-brief light pulses,"The method involves decomposing an ultra-brief light pulse (Ii) into pulses respectively denominating a signal pulse (Is) and a primary reference pulse (Irp), of different polarization or direction of propagation, where phase characteristics of the pulses are identical to the light pulse. Interaction is carried out between the primary pulse and a non-linear optical material (DMNL) to generate a secondary reference pulse (Irs). Spectral or spatial interferometric measurement is carried out by recombining the secondary pulse and the signal pulse with given or null time and angular offsets. An independent claim is also included for a device for measuring a spectral phase or combined spectral and spatial phase of an ultra-brief light pulse.",FASTLITE,KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS,FASTLITE (2009-12-30),https://lens.org/029-770-545-724-687,Granted Patent,yes,1,0,8,8,0,G01J11/00;;G01J11/00,G01J11/00,,1,0,,,"DORRER C ET AL: ""Characterization of the spectral phase of ultrashort light pulses"" COMPTES RENDUS DE L'ACADEMIE DES SCIENCES, SERIE IV (PHYSIQUE, ASTROPHYSIQUE) EDITIONS ELSEVIER FRANCE, vol. 2, no. 10, décembre 2001 (2001-12), pages 1415-1426, XP002489017 ISSN: 1296-2147",ACTIVE
10,EP,A1,EP 2075556 A1,133-289-673-505-349,2009-07-01,2009,EP 08291179 A,2008-12-12,FR 0709092 A,2007-12-26,Method and device for measuring the spectral phase or the combined spectral and spatial phase of ultra-brief light pulses,"Le procédé et le dispositif pour la mesure de la phase spectrale ou de phases spectrale et spatiale combinées d'impulsions lumineuses ultra brèves, consistent à effectuer : 
- une décomposition (S) de l'impulsion lumineuse (Ii) à mesurer en deux répliques identiques dénommées respectivement impulsion signal (Is) et impulsion de référence primaire (Irp), de polarisation ou de direction différentes et dont les caractéristiques de phase sont essentiellement identiques à l'impulsion d'origine (Ii), 
- un filtrage temporel (DMNL) de l'impulsion de référence primaire (Irp) par une interaction non linéaire générant une impulsion de référence secondaire (Irs) de fréquence moyenne essentiellement identique et de largeur spectrale supérieure à la largeur spectrale de l'impulsion de référence primaire (Irp), 
- une mesure d'interférométrie spectrale (SPEC) par recombinaison (R) de cette impulsion de référence secondaire (Irs) et de l'impulsion signal (Is) avec un décalage temporel donné.
",FASTLITE,KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS,FASTLITE (2009-12-30),https://lens.org/133-289-673-505-349,Patent Application,yes,3,3,8,8,0,G01J11/00;;G01J11/00,G01J11/00,,10,8,156-510-756-511-650;;151-492-081-225-227;;156-510-756-511-650;;023-694-287-179-339;;064-227-735-028-37X;;027-302-923-453-539;;065-157-426-060-590;;061-775-067-799-029,10.1016/s1296-2147(01)01279-3;;10.1364/opn.7.3.000023;;10.1016/s1296-2147(01)01279-3;;10.1364/josaa.10.001101;;18087344;;10.1364/ol.23.000792;;10.1007/s00340-002-0912-x;;10.1109/3.914397;;10.1364/josab.22.002635,"DORRER C ET AL: ""Characterization of the spectral phase of ultrashort light pulses"", COMPTES RENDUS DE L'ACADEMIE DES SCIENCES, SERIE IV (PHYSIQUE, ASTROPHYSIQUE) EDITIONS ELSEVIER FRANCE, vol. 2, no. 10, December 2001 (2001-12-01), pages 1415 - 1426, XP002489017, ISSN: 1296-2147;;I.A.WALMSLEY; R.TREBINO: ""Measuring fast pulses with slow detectors"", OPTICS AND PHOTONICS NEWS, vol. 7, no. 3, March 1996 (1996-03-01), pages 23, XP008013232;;C.DORRER; M. JOFFRE: ""Characterization of the spectral phase of ultrashort light pulses"", C.R.ACAD.SC.PARIS, T.2, 2001, pages 1415 - 1426, XP002489017, DOI: doi:10.1016/S1296-2147(01)01279-3;;R.TREBINO; D.J.KANE: ""Using phase retrieval to measure the intensity and phase of ultrashort pulses: Frequency Resolved Optical Gating"", J.OPT.SOC.AM.AL, vol. 1, 1993, pages 2429 - 2437;;C.IACONIS; I.A. WALMSLEY: ""Spectral Phase Interferometry for Direct Electric field Reconstruction of ultrashort optical pulses"", OPT.LETT, vol. 23, 1998, pages 729 - 794;;C.DORRER; E.M.KOSIK; I.A.WALMSLEY: ""Spatio-temporal characterization of the electric filed of ultrashort optical pulses using two-dimensionnal shearing interferometry"", APP.PHYS.B, vol. 74, 2002, pages 209 - 217;;D.E. LEAIRD; A.M. WEINER: ""Femtosecond direct space-to-time pulse shaping"", IEEE JOURNAL OF QUANTUM ELECTRONICS, vol. 37, 2001, pages 494 - 504;;A. JULLIEN ET AL.: ""Nonlinear polarization rotation of elliptical light in cubic crystals, with application to cross-polarized wave génération"", JOURNAL OF OPTICAL SOCIETY OF AMERICA B, vol. 22, 2005, pages 2635;;FROEHLY C.; LACOURT A.; VIENOT J.C.: ""Notions de réponse impulsionnelle et de fonction de transfert temporelles des pupilles optiques, justifications expérimentales et applications"", J. OPT. (PARIS, vol. 4, 1973, pages 183;;BORN; WOLF: ""Principle of Optics"", 1980, PERGAMON PRESS",ACTIVE
11,CN,A,CN 115348901 A,026-829-085-838-230,2022-11-15,2022,CN 202180025000 A,2021-03-17,US 202063000814 P;;US 202117181562 A;;US 2021/0022701 W,2020-03-27,Dispensing unit with fixed flexible diaphragm seal,"A dispensing unit (40) of a dispensing system (10) configured to dispense viscous material on an electronic substrate, the dispensing unit comprising a support housing (42) and a fluid housing (44) supported by the support housing. The fluid housing includes a chamber and an inlet configured to deliver viscous material from the material feed tube to the chamber. The dispensing unit further includes a nozzle assembly (46) releasably secured to the housing and configured to close one end of the fluid housing. The dispensing unit further includes a reciprocating piston (62) partially disposed within the chamber of the fluid housing. The piston is configured to dispense the viscous material from the nozzle assembly. The dispensing unit further includes a stationary flexible diaphragm seal (70) configured to be secured to the fluid housing and the piston.",ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J,,https://lens.org/026-829-085-838-230,Patent Application,no,0,0,7,7,0,B05B1/3046;;B05C5/0225;;B05C11/1034;;B05C5/0216;;B05C11/1034;;B05C5/0225;;B05B1/3046;;B05C5/0216;;F16K41/04;;B05C11/1026;;F16K41/04;;B05C11/1026;;B05C5/0225;;B05B1/3046;;B05C5/0216,B05C5/02;;B05C11/10,,0,0,,,,PENDING
12,AT,T1,AT E456787 T1,043-617-125-022-28X,2010-02-15,2010,AT 08291179 T,2008-12-12,FR 0709092 A,2007-12-26,VERFAHREN UND VORRICHTUNG ZUM MESSEN DER SPEKTRALPHASE ODER DER KOMBINATION AUS SPEKTRALPHASE UND RÄUMLICHER PHASE VON ULTRAKURZEN LICHTIMPULSEN,"The method involves decomposing an ultra-brief light pulse (Ii) into pulses respectively denominating a signal pulse (Is) and a primary reference pulse (Irp), of different polarization or direction of propagation, where phase characteristics of the pulses are identical to the light pulse. Interaction is carried out between the primary pulse and a non-linear optical material (DMNL) to generate a secondary reference pulse (Irs). Spectral or spatial interferometric measurement is carried out by recombining the secondary pulse and the signal pulse with given or null time and angular offsets. An independent claim is also included for a device for measuring a spectral phase or combined spectral and spatial phase of an ultra-brief light pulse.",FASTLITE,KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS,,https://lens.org/043-617-125-022-28X,Granted Patent,no,0,0,8,8,0,G01J11/00;;G01J11/00,,,0,0,,,,INACTIVE
13,US,A1,US 2009/0168070 A1,057-326-013-208-74X,2009-07-02,2009,US 34522908 A,2008-12-29,FR 0709092 A,2007-12-26,METHOD AND DEVICE FOR MEASURING THE SPECTRAL PHASE OR THE COMBINED SPECTRAL AND SPATIAL PHASES OF ULTRA SHORT LIGHT PULSES,"The method and device for measuring the spectral phase or combined spectral and spatial phases of ultra short light pulses, consisting of performing: a decomposition of the light pulse to be measured in two identical replies called signal pulse and primary reference pulse, respectively, of different polarization or direction and the phase characteristics of which are essentially identical to the original pulse,a temporal filtering of the primary reference pulse by a nonlinear interaction generating a secondary reference pulse of average frequency essentially identical and of spectral width greater than the spectral width of the primary reference pulse,a spectral interferometry measurement by recombination of this secondary reference pulse and the signal pulse with a given temporal offset.",FASTLITE,KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS,FASTLITE (2008-10-13),https://lens.org/057-326-013-208-74X,Patent Application,yes,2,5,8,8,0,G01J11/00;;G01J11/00,G01J3/45,356/453,0,0,,,,ACTIVE
14,KR,A,KR 20220150406 A,051-572-081-232-245,2022-11-10,2022,KR 20227036664 A,2021-03-17,US 202063000814 P;;US 202117181562 A;;US 2021/0022701 W,2020-03-27,고정식 플랙시블 다이어프램 밀봉부를 갖는 분배 유닛,전자 기판 상에 점성 물질을 분배하도록 구성된 분배 시스템의 분배 유닛은 지지 하우징 및 상기 지지 하우징에 의해 지지되는 유체 하우징을 포함한다. 상기 유체 하우징은 챔버와 물질 공급 튜브로부터 상기 챔버로 점성 물질을 전달하도록 구성된 유입구를 포함한다. 상기 분배 유닛은 상기 지지 하우징에 해제 가능하게 고정되고 상기 유체 하우징의 단부를 폐쇄하도록 구성된 노즐 어셈블리를 더 포함한다. 상기 분배 유닛은 상기 유체 하우징의 상기 챔버 내에 부분적으로 배치된 왕복 피스톤을 더 포함한다. 상기 피스톤은 상기 노즐 어셈블리로부터 점성 물질이 분배되게 하도록 구성된다. 상기 분배 유닛은 상기 유체 하우징 및 상기 피스톤에 고정되도록 구성된 고정식 플렉시블 다이어프램 밀봉부를 추가로 포함한다.,ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J,,https://lens.org/051-572-081-232-245,Patent Application,no,0,0,7,7,0,B05B1/3046;;B05C5/0225;;B05C11/1034;;B05C5/0216;;B05C11/1034;;B05C5/0225;;B05B1/3046;;B05C5/0216;;F16K41/04;;B05C11/1026;;F16K41/04;;B05C11/1026;;B05C5/0225;;B05B1/3046;;B05C5/0216,B05C11/10;;B05B1/30;;B05C5/02;;F16K41/04,,0,0,,,,PENDING
15,FR,B1,FR 2925956 B1,078-490-162-370-376,2010-01-15,2010,FR 0709092 A,2007-12-26,FR 0709092 A,2007-12-26,PROCEDE ET DISPOSITIF POUR LA MESURE DE LA PHASE SPECTRALE OU DE PHASES SPECTRALE ET SPATIALE COMBINEES D'IMPULSIONS LUMINEUSES ULTRA BREVES.,"The method involves decomposing an ultra-brief light pulse (Ii) into pulses respectively denominating a signal pulse (Is) and a primary reference pulse (Irp), of different polarization or direction of propagation, where phase characteristics of the pulses are identical to the light pulse. Interaction is carried out between the primary pulse and a non-linear optical material (DMNL) to generate a secondary reference pulse (Irs). Spectral or spatial interferometric measurement is carried out by recombining the secondary pulse and the signal pulse with given or null time and angular offsets. An independent claim is also included for a device for measuring a spectral phase or combined spectral and spatial phase of an ultra-brief light pulse.",FASTLITE,KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS,,https://lens.org/078-490-162-370-376,Granted Patent,no,0,0,8,8,0,G01J11/00;;G01J11/00,G01J11/00;;G02F1/19,,0,0,,,,INACTIVE
16,DE,D1,DE 602008000615 D1,111-028-035-616-446,2010-03-18,2010,DE 602008000615 T,2008-12-12,FR 0709092 A,2007-12-26,Verfahren und Vorrichtung zum Messen der Spektralphase oder der Kombination aus Spektralphase und räumlicher Phase von ultrakurzen Lichtimpulsen,"The method involves decomposing an ultra-brief light pulse (Ii) into pulses respectively denominating a signal pulse (Is) and a primary reference pulse (Irp), of different polarization or direction of propagation, where phase characteristics of the pulses are identical to the light pulse. Interaction is carried out between the primary pulse and a non-linear optical material (DMNL) to generate a secondary reference pulse (Irs). Spectral or spatial interferometric measurement is carried out by recombining the secondary pulse and the signal pulse with given or null time and angular offsets. An independent claim is also included for a device for measuring a spectral phase or combined spectral and spatial phase of an ultra-brief light pulse.",FASTLITE,KAPLAN DANIEL;;OKSENHENDLER THOMAS;;FORGET NICOLAS,,https://lens.org/111-028-035-616-446,Granted Patent,no,0,0,8,8,0,G01J11/00;;G01J11/00,G01J11/00,,0,0,,,,ACTIVE
17,TW,A,TW 202313204 A,062-460-463-623-690,2023-04-01,2023,TW 111128562 A,2022-07-29,US 202117392998 A,2021-08-03,Tilt and rotate dispenser having motion control,"A dispensing system includes a frame, a support coupled to the frame, a dispensing unit configured to dispense viscous material, and a gantry assembly coupled to the frame. The gantry assembly includes a gantry configured to support the dispensing 5 unit and to move the dispensing unit in x-axis, y-axis and z-axis directions and a tilt and rotate subassembly configured to tilt and rotate the dispensing unit. The dispensing system further includes a controller configured to control dispensing unit and the gantry assembly to perform a dispense operation on the electronic substrate. The controller is configured to simultaneously coordinate the movement of the gantry assembly and the tilt 10 and rotate subassembly to position and orient the nozzle of the dispensing unit a predetermined distance and orientation from the electronic substrate while dispensing material along a three-dimensional path.",ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J;;REID SCOTT A,,https://lens.org/062-460-463-623-690,Patent of Addition,no,0,0,4,4,0,H05K13/0469;;H05K13/0815;;B05C5/0225;;B05C11/1015;;H05K13/0469;;H05K2203/0126,B05B3/02;;B05C5/02;;H05K3/12;;H05K13/04,,0,0,,,,PENDING
18,US,A1,US 2023/0041453 A1,066-895-104-786-875,2023-02-09,2023,US 202117393003 A,2021-08-03,US 202117393003 A,2021-08-03,TILT AND ROTATE DISPENSER HAVING MATERIAL FLOW RATE CONTROL,"A dispensing system includes a frame, a support coupled to the frame, a dispensing unit configured to dispense viscous material, and a gantry assembly coupled to the frame. The gantry assembly includes a gantry configured to support the dispensing unit and to move the dispensing unit in x-axis, y-axis and z-axis directions and a tilt and rotate subassembly configured to tilt and rotate the dispensing unit. The dispensing system further includes a controller configured to control dispensing unit and the gantry assembly to perform a dispense operation on the electronic substrate. The controller is configured to control the dispensing unit to dispense material from the nozzle of the dispensing unit at a flow rate configured to deposit a desired amount or density of material on the electronic substrate along a three-dimensional path.",ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J;;REID SCOTT A,ILLINOIS TOOL WORKS INC (2022-01-31),https://lens.org/066-895-104-786-875,Patent Application,yes,3,0,4,4,0,H05K13/0469;;B05B13/0415;;B05C5/02;;B05C5/0216;;H01L21/6715,B05B13/04;;H01L21/67,,0,0,,,,ACTIVE
19,TW,A,TW 202320917 A,084-413-561-617-813,2023-06-01,2023,TW 111123813 A,2022-06-27,US 202117393003 A,2021-08-03,Tilt and rotate dispenser having material flow rate control,"A dispensing system includes a frame, a support coupled to the frame, a dispensing unit configured to dispense viscous material, and a gantry assembly coupled to the frame. The gantry assembly includes a gantry configured to support the dispensing unit and to move the dispensing unit in x-axis, y-axis and z-axis directions and a tilt and rotate subassembly configured to tilt and rotate the dispensing unit. The dispensing system further includes a controller configured to control dispensing unit and the gantry assembly to perform a dispense operation on the electronic substrate. The controller is configured to control the dispensing unit to dispense material from the nozzle of the dispensing unit at a flow rate configured to deposit a desired amount or density of material on the electronic substrate along a three-dimensional path.",ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J;;REID SCOTT A,,https://lens.org/084-413-561-617-813,Patent of Addition,no,0,0,4,4,0,H05K13/0469;;B05B13/0415;;B05C5/02;;B05C5/0216;;H01L21/6715,B05B13/04;;B05C5/02;;H01L21/67;;H05K13/04,,0,0,,,,PENDING
20,US,A1,US 2023/0038567 A1,118-825-044-582-045,2023-02-09,2023,US 202117392998 A,2021-08-03,US 202117392998 A,2021-08-03,TILT AND ROTATE DISPENSER HAVING MOTION CONTROL,"A dispensing system includes a frame, a support coupled to the frame, a dispensing unit configured to dispense viscous material, and a gantry assembly coupled to the frame. The gantry assembly includes a gantry configured to support the dispensing unit and to move the dispensing unit in x-axis, y-axis and z-axis directions and a tilt and rotate subassembly configured to tilt and rotate the dispensing unit. The dispensing system further includes a controller configured to control dispensing unit and the gantry assembly to perform a dispense operation on the electronic substrate. The controller is configured to simultaneously coordinate the movement of the gantry assembly and the tilt and rotate subassembly to position and orient the nozzle of the dispensing unit a predetermined distance and orientation from the electronic substrate while dispensing material along a three-dimensional path.",ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J;;REID SCOTT A,ILLINOIS TOOL WORKS INC (2022-01-31),https://lens.org/118-825-044-582-045,Patent Application,yes,36,0,4,4,0,H05K13/0469;;H05K13/0815;;B05C5/0225;;B05C11/1015;;H05K13/0469;;H05K2203/0126,H05K13/04;;B05C5/02;;B05C11/10;;H05K13/08,,0,0,,,,ACTIVE
21,US,B2,US 11904337 B2,115-512-157-157-639,2024-02-20,2024,US 202117393003 A,2021-08-03,US 202117393003 A,2021-08-03,Tilt and rotate dispenser having material flow rate control,"A dispensing system includes a frame, a support coupled to the frame, a dispensing unit configured to dispense viscous material, and a gantry assembly coupled to the frame. The gantry assembly includes a gantry configured to support the dispensing unit and to move the dispensing unit in x-axis, y-axis and z-axis directions and a tilt and rotate subassembly configured to tilt and rotate the dispensing unit. The dispensing system further includes a controller configured to control dispensing unit and the gantry assembly to perform a dispense operation on the electronic substrate. The controller is configured to control the dispensing unit to dispense material from the nozzle of the dispensing unit at a flow rate configured to deposit a desired amount or density of material on the electronic substrate along a three-dimensional path.",ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J;;REID SCOTT A,,https://lens.org/115-512-157-157-639,Granted Patent,yes,42,0,4,4,0,H05K13/0469;;B05B13/0415;;B05C5/02;;B05C5/0216;;H01L21/6715,B05B13/04;;B05C5/02;;H01L21/67,,1,0,,,"International Search Report and Written Opinion from International Application No. PCT/US2022/030890 dated Sep. 8, 2022.",ACTIVE
22,US,B2,US 11805634 B2,097-704-174-551-086,2023-10-31,2023,US 202117392998 A,2021-08-03,US 202117392998 A,2021-08-03,Tilt and rotate dispenser having motion control,"A dispensing system includes a frame, a support coupled to the frame, a dispensing unit configured to dispense viscous material, and a gantry assembly coupled to the frame. The gantry assembly includes a gantry configured to support the dispensing unit and to move the dispensing unit in x-axis, y-axis and z-axis directions and a tilt and rotate subassembly configured to tilt and rotate the dispensing unit. The dispensing system further includes a controller configured to control dispensing unit and the gantry assembly to perform a dispense operation on the electronic substrate. The controller is configured to simultaneously coordinate the movement of the gantry assembly and the tilt and rotate subassembly to position and orient the nozzle of the dispensing unit a predetermined distance and orientation from the electronic substrate while dispensing material along a three-dimensional path.",ILLINOIS TOOL WORKS,FORGET RONALD J;;KARLINSKI THOMAS J;;REID SCOTT A,ILLINOIS TOOL WORKS INC (2022-01-31),https://lens.org/097-704-174-551-086,Granted Patent,yes,43,0,4,4,0,H05K13/0469;;H05K13/0815;;B05C5/0225;;B05C11/1015;;H05K13/0469;;H05K2203/0126,B05C5/02;;B05C11/10;;H05K13/04;;H05K13/08,,2,0,,,"International Search Report and Written Opinion from International Application No. PCT/US2022/030890 dated Sep. 8, 2022.;;International Search Report and Written Opinion from International Application No. PCT/US2022/030908 dated Sep. 6, 2022.",ACTIVE
23,DE,A1,DE 10025689 A1,159-709-178-491-981,2001-12-06,2001,DE 10025689 A,2000-05-24,DE 10025689 A,2000-05-24,Verfahren und Vorrichtung zum Beschichten von mindestens einem Wischgummi,"The invention relates to a method for coating at least one wiper-blade element (10) consisting of an elastomeric material. According to said method, the surface of the wiper-blade element (10) is first cleaned and activated by a plasma and in a subsequent CVD process, a coating material is converted into a plasmatic state and forms at least one protective layer (64) on the surface of the wiper-blade element (10), whilst a high-frequency voltage is applied via an electrode (56) to the area of the wiper-blade element (10) which faces away from the protective layer (64). The invention is characterised in that, before being introduced into a treatment chamber (32, 34, 36, 38, 40), the wiper-blade element (10) is cut to the correct usable length (66) from a strip profile and positioned on an electrode plate (56), in such a way that its wiper-element lip (18) is approximately perpendicular to the electrode plate (56) which extends on both sides of the wiper-blade element (10) and the latter is then exposed to a plasma stream (50).",BOSCH GMBH ROBERT,BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET JEANNE,,https://lens.org/159-709-178-491-981,Patent Application,no,2,1,10,10,0,B60S2001/3829;;B60S2001/3829;;C23C16/44;;C23C16/458;;C23C16/458;;C23C16/0245;;C23C16/0245;;C23C16/509;;C23C16/509,B60S1/38;;C08J7/06;;C23C16/02;;C23C16/458;;C23C16/509,,0,0,,,,DISCONTINUED
24,DE,D1,DE 50110811 D1,197-848-397-772-482,2006-10-05,2006,DE 50110811 T,2001-05-09,DE 10025689 A;;DE 0101769 W;;DE 50110811 T,2000-05-24,VERFAHREN UND VORRICHTUNG ZUM BESCHICHTEN VON MINDESTENS EINEM WISCHGUMMI,,BOSCH GMBH ROBERT,BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET-FUNK JEANNE,,https://lens.org/197-848-397-772-482,Granted Patent,no,0,0,10,10,0,B60S2001/3829;;B60S2001/3829;;C23C16/44;;C23C16/458;;C23C16/458;;C23C16/0245;;C23C16/0245;;C23C16/509;;C23C16/509,B60S1/38;;C08J7/06;;C23C16/02;;C23C16/455;;C23C16/458;;C23C16/509,,0,0,,,,EXPIRED
25,US,A1,US 2002/0164422 A1,038-127-193-745-276,2002-11-07,2002,US 4976302 A,2002-06-04,DE 10025689 A;;DE 0101769 W,2000-05-24,Method and device for coating at least one wiper-blade element,"
    The invention is based on a method for coating at least one wiper blade element ( 10 ) made of an elastomer material, in which first, the surface of the wiper blade element ( 10 ) is cleaned and activated by means of a plasma, and then in a CVD process, a coating material is brought into a plasma state and at least one protective coating ( 64 ) forms on the surface of the wiper blade element ( 10 ), where a high-frequency voltage is applied to the region of the wiper blade element ( 10 ) oriented away from the protective layer ( 64 ) by means of an electrode ( 56 ). 

    The invention proposes that before being brought into a treatment chamber ( 32, 34, 36, 38, 40, 74 ), the wiper blade element ( 10 ) be cut to a useful length ( 66 ) from a profiled band and placed on an electrode plate ( 56 ) so that its wiper lip ( 18 ) stands approximately perpendicular to the electrode plate ( 56 ), which extends to both sides of the wiper blade element ( 10 ), and is subjected to a plasma flow ( 50 ). (FIG. 2 ) 
",BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET-FUNK JEANNE,BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET-FUNK JEANNE,ROBERT BOSCH GMBH (2001-12-12),https://lens.org/038-127-193-745-276,Patent Application,yes,1,12,10,10,0,B60S2001/3829;;B60S2001/3829;;C23C16/44;;C23C16/458;;C23C16/458;;C23C16/0245;;C23C16/0245;;C23C16/509;;C23C16/509,B60S1/38;;C08J7/06;;C23C16/02;;C23C16/458;;C23C16/509,427/255.28;;427/534;;118/719;;118/715;;118/723,0,0,,,,EXPIRED
26,EP,A1,EP 1289807 A1,096-905-493-607-934,2003-03-12,2003,EP 01944921 A,2001-05-09,DE 0101769 W;;DE 10025689 A,2000-05-24,METHOD AND DEVICE FOR COATING AT LEAST ONE WIPER-BLADE ELEMENT,,BOSCH GMBH ROBERT,BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET-FUNK JEANNE,,https://lens.org/096-905-493-607-934,Patent Application,yes,0,0,10,10,0,B60S2001/3829;;B60S2001/3829;;C23C16/44;;C23C16/458;;C23C16/458;;C23C16/0245;;C23C16/0245;;C23C16/509;;C23C16/509,B60S1/38;;C08J7/06;;C23C16/02;;C23C16/458;;C23C16/509,,1,0,,,See references of WO 0189893A1,EXPIRED
27,EP,B1,EP 1289807 B1,098-289-574-364-58X,2006-08-23,2006,EP 01944921 A,2001-05-09,DE 0101769 W;;DE 10025689 A,2000-05-24,METHOD AND DEVICE FOR COATING AT LEAST ONE WIPER-BLADE ELEMENT,,BOSCH GMBH ROBERT,BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET-FUNK JEANNE,,https://lens.org/098-289-574-364-58X,Granted Patent,yes,2,0,10,10,0,B60S2001/3829;;B60S2001/3829;;C23C16/44;;C23C16/458;;C23C16/458;;C23C16/0245;;C23C16/0245;;C23C16/509;;C23C16/509,B60S1/38;;C08J7/06;;C23C16/02;;C23C16/455;;C23C16/458;;C23C16/509,,0,0,,,,EXPIRED
28,WO,A1,WO 2001/089893 A1,194-521-355-053-355,2001-11-29,2001,DE 0101769 W,2001-05-09,DE 10025689 A,2000-05-24,METHOD AND DEVICE FOR COATING AT LEAST ONE WIPER-BLADE ELEMENT,"The invention relates to a method for coating at least one wiper-blade element (10) consisting of an elastomeric material. According to said method, the surface of the wiper-blade element (10) is first cleaned and activated by a plasma and in a subsequent CVD process, a coating material is converted into a plasmatic state and forms at least one protective layer (64) on the surface of the wiper-blade element (10), whilst a high-frequency voltage is applied via an electrode (56) to the area of the wiper-blade element (10) which faces away from the protective layer (64). The invention is characterised in that, before being introduced into a treatment chamber (32, 34, 36, 38, 40), the wiper-blade element (10) is cut to the correct usable length (66) from a strip profile and positioned on an electrode plate (56), in such a way that its wiper-element lip (18) is approximately perpendicular to the electrode plate (56) which extends on both sides of the wiper-blade element (10) and the latter is then exposed to a plasma stream (50).",BOSCH GMBH ROBERT;;BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET FUNK JEANNE,BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET-FUNK JEANNE,,https://lens.org/194-521-355-053-355,Patent Application,yes,2,0,10,10,0,B60S2001/3829;;B60S2001/3829;;C23C16/44;;C23C16/458;;C23C16/458;;C23C16/0245;;C23C16/0245;;C23C16/509;;C23C16/509,B60S1/38;;C08J7/06;;C23C16/02;;C23C16/458;;C23C16/509,,0,0,,,,PATENTED
29,ES,T3,ES 2269422 T3,125-759-728-284-699,2007-04-01,2007,ES 01944921 T,2001-05-09,DE 10025689 A,2000-05-24,PROCEDIMIENTO Y DISPOSITIVO PARA RECUBRIR AL MENOS UNA GOMA DE LIMPIAPARABRISAS.,"Procedimiento para recubrir goma de limpiaparabrisas (10) de un material elastomérico, en el que primero se limpia y activa la superficie del material elastomérico (10) mediante un plasma, y en el que después un material de recubrimiento se pasa en un proceso CVD a un estado en forma de plasma y forma al menos una capa protectora (64) sobre la superficie del material (10), aplicándose sobre la región del material (10) alejada de la capa protectora (64) una tensión de alta frecuencia a través de un electrodo (56), caracterizado porque el material (10) se corta antes de su introducción en una cámara de tratamiento (32, 34, 36, 38, 40, 74) a partir de una banda perfilada, a una longitud (66) lista para usarse, para formar diferentes gomas de limpiaparabrisas, se dispone encima de una placa de electrodos (56) y se expone a una corriente de plasma (50).",BOSCH GMBH ROBERT,BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET-FUNK JEANNE,,https://lens.org/125-759-728-284-699,Granted Patent,no,0,0,10,10,0,B60S2001/3829;;B60S2001/3829;;C23C16/44;;C23C16/458;;C23C16/458;;C23C16/0245;;C23C16/0245;;C23C16/509;;C23C16/509,B60S1/38;;C08J7/06;;C23C16/02;;C23C16/455;;C23C16/458;;C23C16/509,,0,0,,,,EXPIRED
30,US,B2,US 6793978 B2,095-350-139-472-624,2004-09-21,2004,US 4976302 A,2002-06-04,DE 10025689 A;;DE 0101769 W,2000-05-24,Method and device for coating at least one wiper-blade element,"
    The invention is based on a method for coating at least one wiper blade element (  10  ) made of an elastomer material, in which first, the surface of the wiper blade element (  10  ) is cleaned and activated by means of a plasma, and then in a CVD process, a coating material is brought into a plasma state and at least one protective coating (  64  ) forms on the surface of the wiper blade element (  10  ), where a high-frequency voltage is applied to the region of the wiper blade element (  10  ) oriented away from the protective layer (  64  ) by means of an electrode (  56  ). 

    The invention proposes that before being brought into a treatment chamber (  32, 34, 36, 38, 40, 74  ), the wiper blade element (  10  ) be cut to a useful length (  66  ) from a profiled band and placed on an electrode plate (  56  ) so that its wiper lip (  18  ) stands approximately perpendicular to the electrode plate (  56  ), which extends to both sides of the wiper blade element (  10  ), and is subjected to a plasma flow (  50  ). 
",BOSCH GMBH ROBERT,BURGER KURT;;SCHNEIDER GUENTER;;BURGHOFF KLAUS;;WEBER THOMAS;;FORGET-FUNK JEANNE,ROBERT BOSCH GMBH (2001-12-12),https://lens.org/095-350-139-472-624,Granted Patent,yes,8,0,10,10,0,B60S2001/3829;;B60S2001/3829;;C23C16/44;;C23C16/458;;C23C16/458;;C23C16/0245;;C23C16/0245;;C23C16/509;;C23C16/509,B60S1/38;;C08J7/06;;C23C16/02;;C23C16/458;;C23C16/509,427/497;;427/569;;427/534;;427/535;;427/248.1;;427/249.7;;427/255.5;;427/509;;118/719;;X118723 R;;X118723 MP;;X118723 E,0,0,,,,EXPIRED
31,WO,A1,WO 2014/158484 A1,139-813-010-483-683,2014-10-02,2014,US 2014/0017228 W,2014-02-19,US 201313801421 A,2013-03-13,METHOD AND APPARATUS FOR DISPENSING A VISCOUS MATERIAL ON A SUBSTRATE,"A dispenser, configured to dispense material on a substrate, includes a dispensing unit having a housing with a chamber, a piston disposed in the chamber and axially movable within the chamber, and a nozzle coupled to the housing. The nozzle has an orifice co-axial with the chamber of the housing. The dispenser further includes an actuator coupled to the dispensing unit and configured to drive the up-and down movement of the piston, and a compliant assembly coupled to the actuator and the piston. The compliant assembly is configured to permit limited relative travel between the actuator and the piston. A method of dispensing is further disclosed.",ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,,https://lens.org/139-813-010-483-683,Patent Application,yes,5,2,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,G01F11/02;;B05C5/02,,0,0,,,,PENDING
32,CN,A,CN 105008872 A,075-648-513-387-160,2015-10-28,2015,CN 201480013186 A,2014-02-19,US 2014/0017228 W;;US 201313801421 A,2013-03-13,Method and apparatus for dispensing a viscous material on a substrate,"A dispenser, configured to dispense material on a substrate, includes a dispensing unit having a housing with a chamber, a piston disposed in the chamber and axially movable within the chamber, and a nozzle coupled to the housing. The nozzle has an orifice co-axial with the chamber of the housing. The dispenser further includes an actuator coupled to the dispensing unit and configured to drive the up-and down movement of the piston, and a compliant assembly coupled to the actuator and the piston. The compliant assembly is configured to permit limited relative travel between the actuator and the piston. A method of dispensing is further disclosed.",ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,,https://lens.org/075-648-513-387-160,Patent Application,no,7,12,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,G01F11/02;;B05C5/02,,0,0,,,,ACTIVE
33,EP,B1,EP 2972133 B1,157-002-620-079-630,2021-07-28,2021,EP 14709059 A,2014-02-19,US 201313801421 A;;US 2014/0017228 W,2013-03-13,METHOD AND APPARATUS FOR DISPENSING A VISCOUS MATERIAL ON A SUBSTRATE,,ILLINOIS TOOL WORKS,FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A;;DOYLE DENNIS G,,https://lens.org/157-002-620-079-630,Granted Patent,yes,1,0,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05C5/02;;G01F11/02;;B05C11/10,,0,0,,,,ACTIVE
34,US,B2,US 9144818 B2,075-387-675-904-586,2015-09-29,2015,US 201313801421 A,2013-03-13,US 201313801421 A,2013-03-13,Method and apparatus for dispensing a viscous material on a substrate,"A dispenser, configured to dispense material on a substrate, includes a dispensing unit having a housing with a chamber, a piston disposed in the chamber and axially movable within the chamber, and a nozzle coupled to the housing. The nozzle has an orifice co-axial with the chamber of the housing. The dispenser further includes an actuator coupled to the dispensing unit and configured to drive the up- and down movement of the piston, and a compliant assembly coupled to the actuator and the piston. The compliant assembly is configured to permit limited relative travel between the actuator and the piston. A method of dispensing is further disclosed.",ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,ILLINOIS TOOL WORKS INC (2013-06-04),https://lens.org/075-387-675-904-586,Granted Patent,yes,74,3,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05B1/30;;B05C5/02;;B05C11/10;;G01F11/02,,1,0,,,"International Search Report from correspnding PCT/US2014/017228 dated Jun. 3, 2014.",ACTIVE
35,KR,A,KR 20150128674 A,156-159-088-204-94X,2015-11-18,2015,KR 20157022789 A,2014-02-19,US 201313801421 A;;US 2014/0017228 W,2013-03-13,METHOD AND APPARATUS FOR DISPENSING A VISCOUS MATERIAL ON A SUBSTRATE,"기판 상에 재료를 분배하도록 구성되는 분배기가, 챔버를 갖는 하우징, 챔버 내에 배치되고 챔버 내에서 축방향으로 이동 가능한 피스톤, 및 하우징에 결합되는 노즐을 구비하는, 분배 유닛을 포함한다. 노즐은 하우징의 챔버와 동축 상에 놓이는 오리피스를 갖는다. 분배기는, 분배 유닛에 결합되고 피스톤의 상하 이동을 구동하도록 구성되는 액추에이터, 및 액추에이터와 피스톤에 결합되는 유연성 조립체를 더 포함한다. 유연성 조립체는 액추에이터와 피스톤 사이의 제한된 상대 이동을 허용하도록 구성된다. 분배 방법이 추가로 개시된다.",ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,,https://lens.org/156-159-088-204-94X,Patent Application,no,4,3,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05C11/10;;G01F11/02,,0,0,,,,ACTIVE
36,TW,A,TW 201434539 A,010-404-080-519-850,2014-09-16,2014,TW 103104763 A,2014-02-13,US 201313801421 A,2013-03-13,Method and apparatus for dispensing a viscous material on a substrate,"A dispenser, configured to dispense material on a substrate, includes a dispensing unit having a housing with a chamber, a piston disposed in the chamber and axially movable within the chamber, and a nozzle coupled to the housing. The nozzle has an orifice co-axial with the chamber of the housing. The dispenser further includes an actuator coupled to the dispensing unit and configured to drive the up-and down movement of the piston, and a compliant assembly coupled to the actuator and the piston. The compliant assembly is configured to permit limited relative travel between the actuator and the piston. A method of dispensing is further disclosed.",ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,,https://lens.org/010-404-080-519-850,Patent of Addition,no,0,2,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05B9/047,,0,0,,,,ACTIVE
37,PL,T3,PL 2972133 T3,119-119-893-332-305,2021-12-27,2021,PL 14709059 T,2014-02-19,US 201313801421 A;;EP 14709059 A;;US 2014/0017228 W,2013-03-13,METHOD AND APPARATUS FOR DISPENSING A VISCOUS MATERIAL ON A SUBSTRATE,,ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,,https://lens.org/119-119-893-332-305,Patent Application,no,0,0,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,G01F11/02;;B05C5/02;;B05C11/10,,0,0,,,,PENDING
38,JP,A,JP 2019063806 A,071-339-042-315-456,2019-04-25,2019,JP 2019017760 A,2019-02-04,US 201313801421 A,2013-03-13,METHOD FOR DISPENSING VISCOUS MATERIAL ON SUBSTRATE,"To provide a new supply unit for a dispenser which supplies a material on a substrate.SOLUTION: A dispenser, configured to dispense a material on a substrate, includes a dispensing unit. The dispensing unit has a housing with a chamber. A piston which is axially movable is disposed in the chamber, and a nozzle is coupled to the housing. The nozzle has an orifice which is co-axial with the chamber of the housing. The dispenser further includes an actuator which drives the up- and down movement of the piston. The actuator is coupled to the dispensing unit. A compliant assembly is coupled to the actuator and the piston. The compliant assembly is configured to permit limited relative travel between the actuator and the piston.SELECTED DRAWING: Figure 8A",ILLINOIS TOOL WORKS,DENNIS G DOYLE;;RONALD J FORGET;;THOMAS C PRENTICE;;PATSY A MATTERO,,https://lens.org/071-339-042-315-456,Patent Application,no,8,0,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05D1/26;;B05D3/00,,0,0,,,,ACTIVE
39,TW,B,TW I639472 B,006-387-318-865-045,2018-11-01,2018,TW 103104763 A,2014-02-13,US 201313801421 A,2013-03-13,Method and apparatus for dispensing a viscous material on a substrate,,ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,,https://lens.org/006-387-318-865-045,Granted Patent,no,4,0,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,,,0,0,,,,ACTIVE
40,US,A1,US 2014/0263688 A1,070-752-086-912-79X,2014-09-18,2014,US 201313801421 A,2013-03-13,US 201313801421 A,2013-03-13,METHOD AND APPARATUS FOR DISPENSING A VISCOUS MATERIAL ON A SUBSTRATE,"A dispenser, configured to dispense material on a substrate, includes a dispensing unit having a housing with a chamber, a piston disposed in the chamber and axially movable within the chamber, and a nozzle coupled to the housing. The nozzle has an orifice co-axial with the chamber of the housing. The dispenser further includes an actuator coupled to the dispensing unit and configured to drive the up- and down movement of the piston, and a compliant assembly coupled to the actuator and the piston. The compliant assembly is configured to permit limited relative travel between the actuator and the piston. A method of dispensing is further disclosed.",ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,ILLINOIS TOOL WORKS INC (2013-06-04),https://lens.org/070-752-086-912-79X,Patent Application,yes,7,19,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05B1/08,239/1;;239/583,0,0,,,,ACTIVE
41,US,B2,US 9636699 B2,116-000-774-851-594,2017-05-02,2017,US 201514842182 A,2015-09-01,US 201514842182 A;;US 201313801421 A,2013-03-13,Method and apparatus for dispensing a viscous material on a substrate,"A dispenser, configured to dispense material on a substrate, includes a dispensing unit having a housing with a chamber, a piston disposed in the chamber and axially movable within the chamber, and a nozzle coupled to the housing. The nozzle has an orifice co-axial with the chamber of the housing. The dispenser further includes an actuator coupled to the dispensing unit and configured to drive the up- and down movement of the piston, and a compliant assembly coupled to the actuator and the piston. The compliant assembly is configured to permit limited relative travel between the actuator and the piston. A method of dispensing is further disclosed.",ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,ILLINOIS TOOL WORKS INC (2013-06-04),https://lens.org/116-000-774-851-594,Granted Patent,yes,77,3,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05B1/34;;B05C5/02;;B05C11/10;;G01F11/02,,1,0,,,"International Search Report from corresponding PCT/US2014/017228 dated Jun. 3, 2014.",ACTIVE
42,US,A1,US 2015/0367376 A1,049-395-030-993-54X,2015-12-24,2015,US 201514842182 A,2015-09-01,US 201514842182 A;;US 201313801421 A,2013-03-13,METHOD AND APPARATUS FOR DISPENSING A VISCOUS MATERIAL ON A SUBSTRATE,"A dispenser, configured to dispense material on a substrate, includes a dispensing unit having a housing with a chamber, a piston disposed in the chamber and axially movable within the chamber, and a nozzle coupled to the housing. The nozzle has an orifice co-axial with the chamber of the housing. The dispenser further includes an actuator coupled to the dispensing unit and configured to drive the up- and down movement of the piston, and a compliant assembly coupled to the actuator and the piston. The compliant assembly is configured to permit limited relative travel between the actuator and the piston. A method of dispensing is further disclosed.",ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,ILLINOIS TOOL WORKS INC (2013-06-04),https://lens.org/049-395-030-993-54X,Patent Application,yes,4,7,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05C5/02;;B05C11/10,,0,0,,,,ACTIVE
43,EP,A1,EP 2972133 A1,049-928-969-070-747,2016-01-20,2016,EP 14709059 A,2014-02-19,US 201313801421 A;;US 2014/0017228 W,2013-03-13,METHOD AND APPARATUS FOR DISPENSING A VISCOUS MATERIAL ON A SUBSTRATE,,ILLINOIS TOOL WORKS,DOYLE DENNIS G;;FORGET RONALD J;;PRENTICE THOMAS C;;MATTERO PATSY A,,https://lens.org/049-928-969-070-747,Patent Application,yes,0,2,19,19,0,B05C11/1034;;G01F11/021;;B05C5/0225;;B05C11/1034;;G01F11/021;;B05C5/0225,B05C5/02;;G01F11/02,,0,0,,,,ACTIVE
44,WO,A2,WO 2023/150393 A2,027-415-130-140-728,2023-08-10,2023,US 2023/0012540 W,2023-02-07,US 202263307426 P;;US 202263307427 P;;US 202263307429 P,2022-02-07,INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS,"The present disclosure includes MGMT modifications that cause MGMT resistance to MGMT inhibitors. The present disclosure also includes in vivo, in vitro, and ex vivo modification of MGMT -encoding nucleic acids to encode and express an MGMT variant that is resistant to MGMT inhibitors. Inhibitor-resistant MGMT modifications and modification of an MGMT- encoding nucleic can occur or be used in conjunction with a therapeutic modification, e.g., in a single cell. Expression of inhibitor-resistant MGMT can selectively protect modified cells from a selection regimen, such as a selection regimen including an MGMT inhibitor and an alkylating agent. Accordingly, in vivo, in vitro , and ex vivo modification of MGMT -encoding nucleic acids can be used in gene therapy to select for modified cells.",ENSOMA INC;;FRED HUTCHINSON CANCER CENTER,PETERS ROBERT THOMAS;;KIEM HANS-PETER;;BASHYAM ASHVIN REDDY;;FORGET ANTHONY LEO;;HUMBERT OLIVIER,,https://lens.org/027-415-130-140-728,Patent Application,yes,56,0,2,2,487,C12Y201/01063;;C12N9/1007,C12N9/10,,157,113,079-044-075-184-942;;029-648-313-903-345;;038-383-743-124-048;;056-201-471-905-934;;061-048-799-526-041;;009-050-947-857-887;;075-487-220-451-62X;;030-742-444-973-956;;004-357-699-435-048;;032-792-598-225-190;;000-964-302-007-168;;062-374-533-154-906;;014-350-553-906-426;;160-487-702-619-502;;030-665-212-603-239;;030-809-930-204-101;;023-008-904-514-014;;023-060-407-150-57X;;081-266-626-684-413;;064-055-155-783-899;;051-272-007-387-252;;002-829-123-052-618;;067-138-560-843-771;;051-092-680-437-119;;033-598-878-695-469;;049-883-136-583-04X;;005-428-346-383-010;;017-930-939-732-406;;073-732-345-383-396;;036-340-497-289-601;;102-527-762-952-171;;061-053-306-483-829;;028-894-608-461-457;;025-656-845-079-152;;031-536-927-876-375;;123-119-761-441-635;;031-915-272-065-28X;;088-467-700-316-105;;042-352-119-073-980;;073-216-843-796-723;;015-208-818-018-029;;045-943-823-771-524;;060-188-482-047-921;;027-251-949-168-798;;103-863-360-682-745;;065-836-933-444-980;;015-405-829-001-700;;006-761-813-671-798;;007-901-554-488-785;;033-922-481-493-086;;000-595-473-282-366;;064-327-929-319-632;;014-236-767-448-409;;065-464-685-369-592;;044-890-679-548-324;;007-465-024-563-989;;053-772-837-797-983;;010-129-565-484-55X;;045-643-175-966-934;;080-738-486-410-715;;058-179-460-547-881;;029-869-695-513-674;;081-517-201-739-996;;130-013-246-168-150;;139-788-106-138-014;;003-775-182-368-896;;027-938-870-820-019;;131-022-014-524-938;;035-552-117-823-429;;070-994-290-881-89X;;047-920-534-498-155;;043-566-874-827-483;;008-130-612-622-57X;;026-144-786-904-542;;001-599-662-668-123;;046-975-820-411-745;;087-079-382-963-567;;046-312-839-337-568;;007-281-862-233-720;;105-434-295-234-379;;071-397-783-166-086;;002-829-123-052-618;;101-190-661-207-570;;104-598-794-175-478;;045-291-058-804-833;;092-443-027-769-670;;045-300-496-260-786;;006-583-101-268-598;;026-936-964-654-378;;100-739-250-261-90X;;128-414-796-316-213;;119-797-635-454-29X;;052-293-004-352-547;;021-191-725-788-533;;055-917-690-746-440;;071-863-067-753-170;;051-272-007-387-252;;028-309-230-612-216;;030-061-731-105-971;;056-560-300-058-376;;090-705-114-296-933;;011-759-868-125-434;;003-879-682-554-843;;000-219-769-191-19X;;189-106-789-968-668;;055-340-831-684-586;;027-433-574-673-073;;019-031-511-631-819;;125-307-592-221-914;;027-938-870-820-019;;035-552-117-823-429;;070-994-290-881-89X;;020-955-035-059-879,7954470;;10.1016/0888-7543(92)90150-q;;1639402;;10.1093/bioinformatics/5.2.151;;2720464;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1158/0008-5472.can-08-0320;;18676840;;pmc4337843;;27096365;;10.1038/nature17946;;pmc4873371;;10.1038/nrg2842;;20717154;;pmc3547402;;10.1038/nrm3486;;23169466;;1902430;;10.1016/0378-1119(91)90030-f;;28585549;;pmc5467206;;10.1038/ncomms15790;;pmc6126947;;10.1038/nbt.4172;;29813047;;28398345;;10.1038/nbt.3852;;10.1038/nbt.4198;;30125268;;10.1126/science.aas9129;;pmc6368452;;30166441;;pmc5951633;;10.1038/nature26155;;29620737;;29512652;;29875396;;10.1038/s41422-018-0052-4;;pmc6082914;;30341440;;30323312;;pmc6535181;;10.1038/s41576-018-0068-0;;32483364;;10.1038/s41587-020-0535-y;;pmc7723518;;pmc5793859;;10.1126/science.aaq0180;;29070703;;31296651;;10.1126/science.aax7063;;pmc6956565;;10.1073/pnas.1306243110;;24108353;;pmc3831439;;30287096;;10.1016/j.tig.2018.09.004;;10.1016/0022-2836(91)90209-o;;1960725;;8673264;;10.1111/j.1365-2583.1996.tb00048.x;;10090929;;10.1182/blood.v93.7.2208;;10.1182/blood.v93.7.2208.407k12_2208_2216;;10969081;;10.1074/jbc.m006259200;;10.1016/0092-8674(80)90428-6;;6254664;;68958;;10.1016/s0021-9258(17)40156-6;;10.1016/s0079-6603(08)60917-4;;1019344;;7624311;;pmc41402;;10.1073/pnas.92.15.6728;;22049516;;10.1182/blood-2011-04-348904;;10.1016/s0955-0674(00)00204-0;;11248560;;10.1038/emboj.2008.41;;18354502;;pmc2323262;;16096065;;10.1016/j.cell.2005.07.013;;pmc2874221;;10.2174/138920210790886871;;20885819;;9390559;;10.1016/s0092-8674(00)80436-5;;10.1006/jmbi.2000.4047;;10964563;;10.1016/s1525-0016(03)00099-6;;12842434;;10.1038/ng.343;;10.3410/f.1160400.620746;;19412179;;12244327;;10.1038/nbt738;;10.1016/j.ymthe.2005.06.484;;16150650;;14759813;;10.1016/j.ymthe.2003.11.024;;10.1038/nbt.1717;;pmc3356916;;21151124;;pmc10473235;;10.1002/1873-3468.13668;;31705806;;pmc2573189;;10.1128/jvi.01308-08;;18753195;;18235044;;10.1182/blood-2007-10-120329;;10.1016/j.exphem.2008.03.014;;18504066;;11238087;;10.1182/blood.v97.6.1534;;10.1007/s40261-016-0437-4;;27422740;;10.1038/ncomms11007;;pmc4796355;;26975966;;pmc5473067;;10.1159/000477262;;28626366;;10.1016/j.cytogfr.2014.07.011;;25131807;;10.1038/bmt.2008.189;;18622423;;10.1097/moh.0b013e328302f43a;;18536564;;pmc2806229;;9516120;;10.1182/blood.v91.7.2231;;10.1182/blood.v91.7.2231.2231_2231_2239;;10.3324/haematol.13204;;18728024;;pmc1503078;;5640195;;3487351;;10.1182/blood.v68.1.126.126;;6109148;;10.1182/blood-2005-03-1131;;pmc1366491;;15976178;;pmc150801;;10.1172/jci16167;;10.1172/jci200216167;;10.1172/jci0216167;;12393852;;10.1038/nm.2080;;20081862;;pmc2819359;;10523497;;10.1242/jcs.112.21.3603;;10.1016/j.cell.2009.03.045;;pmc2827930;;19379690;;10.1016/0092-8674(91)90064-6;;0001657403;;1657403;;9819428;;10.1128/mcb.18.12.7423;;pmc109323;;16075413;;10.1002/jgm.816;;10.1371/journal.pone.0152684;;27035132;;pmc4818092;;9581836;;10197622;;32814708;;pmc7455141;;10.1172/jci.insight.139538;;pmc9272811;;10.1038/s41596-021-00577-3;;34363069;;10.1172/jci40767;;20551514;;pmc2898586;;31634902;;pmc6907074;;10.1038/s41586-019-1711-4;;10.1038/nbt.4192;;pmc6390938;;30010673;;10.1016/j.stemcr.2014.12.005;;pmc4325197;;25601207;;pmc5706766;;27525524;;10.1038/nm.4170;;31698466;;10.1182/bloodadvances.2019000820;;pmc6855127;;10.1128/jvi.02449-08;;19224987;;pmc2668486;;30195789;;pmc6076213;;10.1016/j.omtn.2018.06.010;;10.1182/blood-2009-10-249326;;20207983;;30287096;;10.1016/j.tig.2018.09.004;;10.1101/2020.07.21.213827;;pmc8847327;;10.1101/2020.12.30.424891;;10.1242/prelights.27128;;10.1038/s41587-021-01025-z;;34650269;;10.1038/s41551-020-00622-8;;pmc7882013;;32989284;;9157998;;pmc310240;;10747039;;10.1093/emboj/19.7.1719;;10.1038/nsmb791;;15221026;;pmc33144;;10.1073/pnas.091601198;;11296271;;8971155;;9500464;;24157870;;pmc4648381;;10.1038/cddis.2013.388;;19060901;;10.1038/ni.1680;;pmc2701568;;31110355;;10.1038/s41587-019-0134-y;;pmc6551276;;32690971;;10.1038/s41587-020-0609-x;;pmc7854778;;10.1038/nbt.4102;;29553573;;10.1073/pnas.1306243110;;24108353;;pmc3831439;;10.1093/nar/gkv1387;;10.1093/nar/gkw812;;10.1093/nar/gkw738;;10.1093/nar/gkw707;;10.1093/nar/gkv1435;;10.1093/nar/gkw896;;10.1093/nar/gkw908;;10.1093/nar/gkv1432;;10.1093/nar/gkw624;;pmc4020053;;10.1073/pnas.1401182111;;24757057;;10.1021/bi00096a009;;8218276;;17482892;;pmc2030992;;10.1016/j.dnarep.2007.03.012;;12727789;;10.1093/carcin/bgg005;;10.1038/s41573-020-0084-6;;33077937;;pmc7721651;;31308540;;10.1038/s41587-019-0178-z;;10.1016/j.ymthe.2004.06.944;;32483365;;10.1038/s41587-020-0509-0;;33097693;;pmc7584657;;10.1038/s41467-020-19136-7;;10.1101/2020.06.09.139782;;10.1126/science.aba8853;;32217751;;pmc7297043;;pmc102527;;10.1093/nar/28.2.393;;10606635;;16075413;;10.1002/jgm.816;;9581836;;10197622;;10.1038/s41587-020-0527-y;;32483363,"""Computational Molecular Biology"", 1988, OXFORD UNIVERSITY PRESS;;CRONE, T. M.GOODTZOVA, KEDARA, SPEGG, A. E., MUTATIONS INHUMAN ALKYLTRANSFERASE IMPARTING RESISTANCE, 1994, pages 6221 - 6227;;GROVSFELD ET AL., CELL, vol. 51, no. 6, 1987, pages 975 - 985;;TAGLE ET AL., GENOMICS, vol. 13, no. 3, 1992, pages 741 - 760;;HIGGINSSHARP, CABIOS, vol. 5, 1989, pages 151 - 153;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;SAMBROOKFRITSCHMANIATIS: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;""GenBank"", Database accession no. 304605-304814;;MILSOM, M. D.JERABEK-WILLEMSEN, MHARRIS, C. E.SCHAMBACH, ABROUN, EBAILEY, JJANSEN, MSCHLEIMER, DNATTAMAI, KWILHELM, J: ""Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells"", CANCER RESEARCH, vol. 68, no. 15, 2008, pages 6171 - 6180;;KLEINSTIVER, NATURE, vol. 533, 2016, pages 420 - 424;;SLAYMAKER, SCIENCE, vol. 351, 2015, pages 84 - 88;;URNOV, NAT REV GENET, vol. 11, no. 9, 2010, pages 636 - 46;;JOUNG, NAT REV MOL CELL BIOL, vol. 14, no. 1, 2013, pages 49 - 55;;WANG, GENE, vol. 99, 1991, pages 31 - 37;;REES, NAT. COMMUN., vol. 8, 2017, pages 15790;;KOBLAN, NAT. BIOTECHNOL, vol. 36, no. 9, 2018, pages 843 - 846;;KOMOR, SCI. ADV., vol. 3, no. 8, 2017, pages 4774;;KIM, NAT. BIOTECHNOL., vol. 35, 2017, pages 475 - 480;;GEHRKE, NAT. BIOTECHNOL., vol. 36, no. 10, 2018, pages 946 - 949;;ABUDAYYEH, SCIENCE, vol. 353, no. 6305, 2016, pages 5573;;NISHIMASU, SCIENCE, vol. 361, no. 6408, 2018, pages 1259 - 1262;;HU, NATURE, vol. 556, 2018, pages 57 - 63;;JIANG, CELL RES, vol. 28, no. 8, 2018, pages 855 - 861;;REES, NAT. REV GENET., vol. 19, no. 12, 2018, pages 770 - 788;;KANTOR, ΣNT. J. MOL. SCI., vol. 21, no. 17, 2020, pages 6240;;GRUNEWALD, JZHOU, RLAREAU, C. A.GARCIA, S. P.IYER, SMILLER, B. R.LANGNER, L. M.HSU, J. Y.ARYEE, M. J.JOUNG, J. K.: ""A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing"", NATURE BIOTECHNOLOGY, vol. 38, no. 7, 2020, pages 861 - 864, XP037187544, DOI: 10.1038/s41587-020-0535-y;;GRUNEWALD, NAT. BIOTECHNOL., vol. 38, 2020, pages 856 - 860;;HARTER, NAT. IMMUNOL., vol. 10, no. 1, 2009, pages 109 - 115;;COX, D. B. T.GOOTENBERG, J. S.ABUDAYYEH, O. O.FRANKLIN, B.KELLNER, M. J.JOUNG, JZHANG, F: ""RNA editing with CRISPR-Cas13"", SCIENCE, vol. 358, no. 6366, 2017, pages 1019 - 1027, XP055491658, DOI: 10.1126/science.aaq0180;;ABUDAYYEH, SCIENCE, vol. 365, 2019, pages 382 - 386;;MONTIEL-GONZALEZ, PNAS, vol. 110, no. 45, 2013, pages 18285 - 18290;;MONTIEL-GONZALEZ, NUC. ACIDS. RES., vol. 44, no. 2, 2016, pages 157;;QU, NAT. BIOTECH., 2019, pages 1059 - 1069;;CHOW, NAT. BIOMED. ENG. DOI: 10.1038/S41551 -020-00622-8, 2020;;HSU, BIORXIV DOI: 10.1101/2020.05.04.077750, 2020;;WIENERT, TRENDS IN GENETICS, vol. 34, no. 12, 2018, pages 927 - 940;;HARDISON ET AL., J. MOL. BIOL., vol. 222, no. 2, 1991, pages 233 - 249;;FRASER ET AL., INSECT MOL. BIOL., vol. 5, 1996, pages 141 - 51;;LI ET AL., BLOOD, vol. 93, no. 7, 1999, pages 2208 - 2216;;GORMAN ET AL., J. BIOL. CHEM., vol. 275, no. 46, 2000, pages 35914 - 35919;;SLIGHTOM ET AL., CELL, vol. 21, no. 3, 1980, pages 647 - 651;;MAROTTA ET AL., J. BIOL. CHEM., vol. 252, no. 14, 1977, pages 5040 - 5053;;MAROTTA ET AL., PROG. NUCLEIC ACID RES. MOL. BIOL., vol. 19, 1976, pages 165 - 175;;SADELAIN ET AL., PNAS, vol. 92, 1995, pages 6728 - 6732;;""NCBI"", Database accession no. NP 000509;;JUAREZ ET AL., BLOOD, vol. 119, no. 3, 2012, pages 707 - 716;;CARTHEW, CURR. OPIN. CELL. BIOL., vol. 13, 2001, pages 244 - 248;;MITRA ET AL., EMBO J., vol. 27, 2008, pages 1097 - 1109;;DING ET AL., CELL, vol. 122, 2005, pages 473 - 83;;MUNOZ-LOPEZGARCIA PEREZ, CURR GENOMICS, vol. 11, no. 2, 2010, pages 115 - 128;;IVICS ET AL., CELL, vol. 91, 1997, pages 501 - 510;;IZSVAK ET AL., J. MOL. BIOL., vol. 302, no. 1, 2000, pages 93 - 102;;GEURTS ET AL., MOLECULAR THERAPY, vol. 8, no. 1, 2003, pages 108 - 117;;MATES ET AL., NATURE GENETICS, vol. 41, 2009, pages 753 - 761;;YANT ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 999 - 1005;;YANT ET AL.: ""undertook the systematic exchange of the N-terminal 95 AA of the SB transposase for alanine"", MOL. CELL BIOL., vol. 24, 2004, pages 9239 - 9247;;BAUS ET AL., MOL. THERAPY, vol. 12, 2005, pages 1148 - 1156;;ZAYED ET AL., MOLECULAR THERAPY, vol. 9, no. 2, 2004, pages 292 - 304;;RICHARDSON ET AL., NATBIOTECHNOL, vol. 34, no. 3, 2016, pages 339 - 44;;SADELAIN ET AL., NATURE REVIEWS, vol. 12, 2012, pages 51 - 58;;PAPAPETROU ET AL., NAT BIOTECHNOL., vol. 29, no. 1, 2011, pages 73 - 8;;LILIEBER, FEBS LETTERS, vol. 593, no. 24, 2019, pages 3623 - 3648;;WANG ET AL., J. VIROL., vol. 82, no. 21, 2008, pages 10567 - 10579;;PALMER ET AL.: ""Methods in Molecular Biology"", vol. 433, 2009, HUMANA PRESS, article ""2009 Gene Therapy Protocols"", pages: 33 - 53;;ZOHREN ET AL., BLOOD, vol. 111, 2008, pages 3893 - 3895;;RAMIREZ ET AL., BLOOD, vol. 113, no. 21, 2009, pages 5094 - 1343;;BRUNNER ET AL., EXP HEMATOL, vol. 36, 2008, pages 1157 - 1166;;BORTEZOMIBGHOBADI ET AL., ASH ANNUAL MEETING ABSTRACTS, 2012, pages 216;;KING ET AL., BLOOD, vol. 97, 2001, pages 1534 - 1542;;KIM ET AL., BLOOD, vol. 128, 2016, pages 2457 - 2461;;ROSARIO ET AL., CLIN DRUG INVESTIG, vol. 36, 2016, pages 913 - 923;;CAO ET AL., NAT COMMUN, vol. 7, 2016, pages 11007;;RICHTER R ET AL., TRANSFUS MED HEMOTHER, vol. 44, 2017, pages 151 - 164;;BENDALLBRADSTOCK, CYTOKINE & GROWTH FACTOR REVIEWS, vol. 25, 2014, pages 355 - 367;;""Regenerative Medicine, Department of Health and Human Services"", 5 August 2006;;""Stem Cell Information"", 2009, DEPARTMENT OF HEALTH AND HUMAN SERVICES, article ""Hematopoietic Stem Cells"";;OLKKONENSTENMARK, INT. REV. CYTOL., vol. 176, 1997, pages 4779 - 4788;;JIN ET AL., BONE MARROW TRANSPLANT, vol. 42, no. 7, 2008, pages 455 - 459;;PELUS, CURR. OPIN. HEMATOL., vol. 15, no. 4, 2008, pages 285 - 292;;PAPAYANNOPOULOU ET AL., BLOOD, vol. 91, 1998, pages 2231 - 2239;;TRICOT ET AL., HAEMATOLOGICA, vol. 93, no. 11, 2008, pages 1739 - 1742;;WEAVER ET AL., BONE MARROW TRANSPLANT, vol. 27, 2001, pages 23 - 29;;ALSEVER ET AL., J. MED., vol. 41, 1941, pages 126;;DE GOWIN ET AL., J. AM. MED. ASSOC., 1940, pages 114 - 850;;SMITH ET AL., J. THOME. CARDIOVASC. SURG., vol. 38, 1959, pages 573;;ROUSTURNER, J. EXP. MED., vol. 23, no. 2, 1916, pages 219 - 237;;HUM, CALIF. MED., vol. 108, no. 3, 1968, pages 218 - 224;;WILLIAMS ET AL., DEV. BIOL., vol. 112, no. 1, 1985, pages 126 - 134;;LU ET AL., EXP. HEMATOL., vol. 14, no. 10, 1986, pages 955 - 962;;LU ET AL., BLOOD, vol. 68, no. 1, 1986, pages 126 - 133;;REISNER ET AL., LANCET, vol. 2, no. 8208-8209, 1980, pages 1320 - 1324;;VARNUM-FINNEY ET AL., BLOOD, vol. 101, 1993, pages 1784 - 1789;;DELANEY ET AL., BLOOD, vol. 106, 2005, pages 2693 - 2699;;OHISHI ET AL., J. CLIN. INVEST., vol. 110, 2002, pages 1165 - 1174;;DELANEY ET AL., NATURE MED, vol. 16, no. 2, 2010, pages 232 - 236;;""Regenerative Medicine"", August 2006, DEPARTMENT OF HEALTH AND HUMAN SERVICES;;SCHLONDORFIANDBLOBEL, J. CELL SCI., vol. 112, 1999, pages 3603 - 3617;;KOPAN ET AL., CELL, vol. 137, 2009, pages 216 - 233;;REBAY ET AL., CELL, vol. 67, 1991, pages 687 - 699;;JARRIAULT ET AL., MOL. CELL. BIOL., vol. 18, 1998, pages 7423 - 7431;;""Remington's Pharmaceutical Sciences"", 1990, MACK PRINTING COMPANY;;WATSON, A. J.MARGISON, G. P.: ""DNA Repair Protocols"", 2000, SPRINGER, article ""0 6-Alkylguanine-DNA Alkytransferase Assay"", pages: 49 - 61;;WOOLFORD, J. GENE MED., vol. 8, no. 1, 2006, pages 29 - 34;;BEHARRY, A. A.NAGEL, Z. D.SAMSON, L. D.KOOL, E. T. K.: ""Fluorogenic real-time reporters of DNA repair by MGMT, a clinical predictor of antitumor drug response"", PLOS ONE, vol. 11, no. 4, 2016, pages 1 - 15;;NAGEL ET AL., PNAS USA, vol. 111, no. 18, 2014, pages 1823 - 32;;PEGG, CANCER RES., vol. 59, 1998, pages 1936 - 1945;;XU-WELLIVER, CANCER RES., vol. 59, no. 7, 1999, pages 1514 - 1519;;WANG, HGEORGAKOPOULOU, ALI, CLIU, ZGIL, SBASHYAM, AYANNAKI, EANAGNOSTOPOULOS, APANDE, AIZSVAK, Z: ""Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements"", JCI INSIGHT, vol. 5, no. 16, 2020, pages 1 - 17;;PIETT ET AL., NAT. PROTOC., vol. 16, no. 9, 2021, pages 4265 - 4298;;ADAIR ET AL., SCI TRANSLATMED, vol. 4, no. 133, 2012, pages 133ra57;;BEARD ET AL., J CLIN INVEST, vol. 120, no. 7, 2010, pages 2345 - 54;;ANZALONE, A. V.RANDOLPH, P. B.DAVIS, J. R.SOUSA, A. A.KOBLAN, L. W.LEVY, J. M.CHEN, P. J.WILSON, C.NEWBY, G. A.RAGURAM, A.: ""Search-and-replace genome editing without double-strand breaks or donor DNA"", NATURE, vol. 576, no. 7785, 2019, pages 149 - 157, XP055899878, DOI: 10.1038/s41586-019-1711-4;;KOSICKI ET AL., NAT BIOTECHNOL, vol. 36, no. 8, 2018, pages 765 - 71;;MCINTOSH ET AL., STEM CELL REPORTS, vol. 4, no. 2, 2015, pages 171 - 80;;TRAXLER ET AL., NAT MED, vol. 22, no. 9, 2016, pages 987 - 90;;METAIS ET AL., BLOOD ADV, vol. 3, no. 21, 2019, pages 3379 - 92;;HUMBERT ET AL., LEUKEMIA, vol. 33, no. 3, 2019, pages 762 - 808;;METAIS ET AL., BLOODADV, vol. 3, no. 21, 2019, pages 3379 - 92;;UZRI ET AL., J VIROL, vol. 83, no. 9, 2009, pages 4174 - 84;;VAIDYANATHAN ET AL., MOL THER NUCLEIC ACIDS, vol. 12, 2018, pages 530 - 42;;KIM ET AL., GENOME RES, 2018;;WIENERT ET AL., PLOSBIOL, vol. 16, no. 7, 2018, pages 2005840;;NOTTA ET AL., BLOOD, vol. 115, no. 18, 2010, pages 3704 - 7;;WIENERT ET AL., TRENDS GENET, vol. 34, no. 12, 2018, pages 927 - 40;;KOMOR ET AL., SCI ADV, vol. 3, no. 8, 2017, pages 4774;;CHEN, LPARK, J. E.PAA, PRAJAKUMAR, P. D.CHEW, Y. T.MANIVANNAN, S. N.CHEW, W. L.: ""Precise and programmable C: G to G: C base editing in genomic DNA"", BIORXIV, 2020;;CHOI, JCHEN, WSUITER, C. C.LEE, CCHARDON, F. M.YANG, WLEITH, ADAZA, R. M.MARTIN, BSHENDURE, J: ""Precise genomic deletions using paired prime editing"", BIORXIV, 2021;;CHOW, R. D.CHEN, J. S.SHEN, J.CHEN, S: ""A web tool for the design of prime-editing guide RNAs"", NATURE BIOMEDICAL ENGINEERING, 2020;;CHRISTIANS, F. C.DAWSON, B. J.COATES, M. M.LOEB, L. A.: ""Creation of human alkyltransferases resistant to O6-benzylguanine"", CANCER RESEARCH, vol. 57, no. 10, 1997, pages 2007 - 2012;;DANIELS, D. S., MOL, C. D., ARVAI, A. S., KANUGULA, S., PEGG, A. E., & TAINER, J. A.: ""Active and alkylated human AGT structures: A novel zinc site, inhibitor and extrahelical base binding"", EMBO JOURNAL, vol. 19, no. 7, pages 1719 - 1730, XP002988818, DOI: 10.1093/emboj/19.7.1719;;DANIELS, D. S.WOO, T. T.LUU, K. X.NOLL, D. M.CLARKE, N. D.PEGG, A. E.TAINER, J. A.: ""DNA binding and nucleotide flipping by the human DNA repair protein AGT"", NATURE STRUCTURAL AND MOLECULAR BIOLOGY, vol. 11, no. 8, 2004, pages 714 - 720, XP009079611, DOI: 10.1038/nsmb791;;DAVIS, B. M.ENCELL, L. P.ZIELSKE, S. P.CHRISTIANS, F. C.LIU, L.FRIEBERT, S. E.LOEB, L. A.GERSON, S. L.: ""Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 9, 2001, pages 4950 - 4954;;EDARA, SKANUGULA, SGOODTZOVA, KPEGG, A. E.: ""Resistance of the human O6-alkylguanine-DNA alkyltransferase containing arginine at codon 160 to inactivation by O6-benzylguanine"", CANCER RESEARCH, vol. 56, no. 24, 1996, pages 5571 - 5575;;ENCELL, L. P.COATES, M. M.LOEB, L. A.: ""Engineering human DNA alkyltransferases for gene therapy using random sequence mutagenesis"", CANCER RESEARCH, vol. 58, no. 5, 1998, pages 1013 - 1020;;FAN, C. H.LIU, W. L.CAO, HWEN, CCHEN, LJIANG, G: ""06-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas"", CELL DEATH AND DISEASE, vol. 4, no. 10, 2013;;HARTNER, J. C.WALKLEY, C. R.LU, JORKIN, S. H.: ""ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling"", NATURE IMMUNOLOGY, vol. 10, no. 1, 2009, pages 109 - 115;;HUANG, T. P.ZHAO, K. T.MILLER, S. M.GAUDELLI, N. M.OAKES, B. L.FELLMANN, CSAVAGE, D. F.LIU, D. R.: ""Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors"", NATURE BIOTECHNOLOGY, vol. 37, no. 6, 2019, pages 626 - 631, XP036900674, DOI: 10.1038/s41587-019-0134-y;;KURT, I. C.ZHOU, RIYER, SGARCIA, S. P.MILLER, B. R.LANGNER, L. M.GRUNEWALD, J.JOUNG, J. K.: ""CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells"", NATURE BIOTECHNOLOGY, 2020;;LI, XWANG, YLIU, YYANG, BWANG, XWEI, JLU, ZZHANG, YWU, JHUANG, X: ""Base editing with a Cpfl-cytidine deaminase fusion"", NATURE BIOTECHNOLOGY, vol. 36, no. 4, 2018, pages 324 - 327;;MONTIEL-GONZALEZ, M. F., VALLECILLO-VIEJO, I., YUDOWSKI, G. A., & ROSENTHAL, J. J. C.: ""Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, no. 45, 2013, pages 18285 - 18290, XP055260494, DOI: 10.1073/pnas.1306243110;;MONTIEL-GONZALEZ, M. F.VALLECILLO-VIEJO, I. C.ROSENTHAL, J. J. C.: ""An efficient system for selectively altering genetic information within mRNAs"", NUCLEIC ACIDS RESEARCH, vol. 44, no. 21, 2016, pages 1 - 12, XP055404024, DOI: 10.1093/nar/gkw738;;NAGEL, Z. D.MARGULIES, C. M.CHAIM, I. A.MCREE, S. K.MAZZUCATO, PAHMAD, AABO, R. P.BUTTY, V. L.FORGET, A. L.SAMSON, L. D.: ""Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 111, no. 18, 2014, pages 1823 - 32, XP055498099, DOI: 10.1073/pnas.1401182111;;PEGG, A. E.BYERS, T. L.SWENN, KBOOSALIS, MSAMSON, LMOSCHEL, R. C.DOLAN, M. E.: ""Mechanism of Inactivation of Human O6-Alkylguanine-DNA Alkyltransferase by O6-Benzylguanine"", BIOCHEMISTRY, vol. 32, no. 45, 1993, pages 11998 - 12006;;PEGG, A. E.FANG, QLOKTIONOVA, N. A.: ""Human variants of O6-alkylguanine-DNA alkyltransferase"", DNA REPAIR, vol. 6, no. 8, 2007, pages 1071 - 1078, XP022155641, DOI: 10.1016/j.dnarep.2007.03.012;;MARGISON, G. P.POVEY, A. C.KAINA, BSANTIBANEZ KOREF, M. F.: ""Variability and regulation of O6-alkylguanine-DNA alkyltransferase"", CARCINOGENESIS, vol. 24, no. 4, 2003, pages 625 - 635;;PORTO, E. M.KOMOR, A. C.SLAYMAKER, I. M.YEO, G. W.: ""Base editing: advances and therapeutic opportunities"", NATURE REVIEWS DRUG DISCOVERY, vol. 19, no. 12, 2020, pages 839 - 859, XP037307087, DOI: 10.1038/s41573-020-0084-6;;QU, LYI, ZZHU, SWANG, CCAO, ZZHOU, ZYUAN, PYU, YTIAN, FLIU, Z: ""Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs"", NATURE BIOTECHNOLOGY, vol. 37, no. 9, 2019, pages 1059 - 1069;;REESE, JLINGAS, KKSENICH, PSWEENEY, CKOC, OGERSON, S: ""Preliminary Results of a Phase I Trial Using Retroviral Gene Transfer of G156A MGMT To Protect Hematopoiesis during BG and BCNU Therapy of Advanced Malignancies"", MOLECULAR THERAPY, vol. 9, May 2004 (2004-05-01), pages 385, XP004635372;;SAKATA, R. C.ISHIGURO, SMORI, HTANAKA, MTATSUNO, KUEDA, HYAMAMOTO, SSEKI, MMASUYAMA, NNISHIDA, K: ""Base editors for simultaneous introduction of C-to-T and A-to-G mutations"", NATURE BIOTECHNOLOGY, vol. 38, no. 7, 2020, pages 865 - 869;;SCHENE, I. F.JOORE, I. P.OKA, RMOKRY, MVAN VUGT, A. H. M.VAN BOXTEL, RVAN DER DOEF, H. P. J.VAN DER LAAN, L. J. W.VERSTEGEN, M. M.: ""Prime editing for functional repair in patient-derived disease models"", NATURE COMMUNICATIONS, vol. 11, no. 1, 2020, pages 1 - 8, XP055930449, DOI: 10.1038/s41467-020-19136-7;;WALTON, R. T.CHRISTIE, K. A.WHITTAKER, M. N.KLEINSTIVER, B. P.: ""Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants"", SCIENCE, vol. 368, no. 6488, 2020, pages 290 - 296, XP055957984, DOI: 10.1126/science.aba8853;;WIBLEY, J. E. A.PEGG, A. E.MOODY, P. C. E.: ""Crystal structure of the human O6-alkylguanine-DNA alkyltransferase"", NUCLEIC ACIDS RESEARCH, vol. 28, no. 2, 2000, pages 393 - 401;;WOOLFORD, L. B.SOUTHGATE, T. D.MARGISON, G. P.MILSOM, M. D.FAIRBAIRN, L. J.: ""The P140K mutant of human O6-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O6-(4-bromothenyl) guanine"", THE JOURNAL OF GENE MEDICINE: A CROSS-DISCIPLINARY JOURNAL FOR RESEARCH ON THE SCIENCE OF GENE TRANSFER AND ITS CLINICAL APPLICATIONS, vol. 8, no. 1, 2006, pages 29 - 34;;XU-WELLIVER, MKANUGULA, SPEGG, A. E.: ""Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine"", CANCER RESEARCH, vol. 58, no. 9, 1998, pages 1936 - 1945;;XU-WELLIVER, M.LEITAO, JKANUGULA, SPEGG, A. E.: ""Alteration of the conserved residue tyrosine-158 to histidine renders human 06-alkylguanine-DNA alkyltransferase insensitive to the inhibitor 06- benzylguanine"", CANCER RESEARCH, vol. 59, no. 7, 1999, pages 1514 - 1519;;ZHANG XZHU BCHEN LXIE LYU WWANG YLI LYIN SYANG LHU H: ""Dual base editor catalyzes both cytosine and adenine base conversions in human cells"", NATURE BIOTECHNOLOGY, vol. 38, no. 7, 2020, pages 856 - 860, XP037187540, DOI: 10.1038/s41587-020-0527-y;;ZHAO, DLI, JLI, SXIN, XHU, MPRICE, M. A.ROSSER, S. J.BI, C.ZHANG, X: ""New base editors change C to A in bacteria and C to G in mammalian cells"", NATURE BIOTECHNOLOGY, 2020",PENDING
45,WO,A3,WO 2023/150393 A3,188-764-702-503-293,2023-09-21,2023,US 2023/0012540 W,2023-02-07,US 202263307426 P;;US 202263307427 P;;US 202263307429 P,2022-02-07,INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS,"The present disclosure includes MGMT modifications that cause MGMT resistance to MGMT inhibitors. The present disclosure also includes in vivo, in vitro, and ex vivo modification of MGMT -encoding nucleic acids to encode and express an MGMT variant that is resistant to MGMT inhibitors. Inhibitor-resistant MGMT modifications and modification of an MGMT- encoding nucleic can occur or be used in conjunction with a therapeutic modification, e.g., in a single cell. Expression of inhibitor-resistant MGMT can selectively protect modified cells from a selection regimen, such as a selection regimen including an MGMT inhibitor and an alkylating agent. Accordingly, in vivo, in vitro , and ex vivo modification of MGMT -encoding nucleic acids can be used in gene therapy to select for modified cells.",ENSOMA INC;;FRED HUTCHINSON CANCER CENTER,PETERS ROBERT THOMAS;;KIEM HANS-PETER;;BASHYAM ASHVIN REDDY;;FORGET ANTHONY LEO;;HUMBERT OLIVIER,,https://lens.org/188-764-702-503-293,Search Report,yes,2,0,2,2,0,C12Y201/01063;;C12N9/1007,C12N9/10,,3,2,035-689-974-207-724;;048-584-302-874-365,10.1016/s0006-2952(99)00095-7;;10423163;;19865182;;10.1038/gt.2009.133,"""methylated-DNA--protein-cysteine methyltransferase isoform X5 [Chloroc - Protein - NCBI"", 1 December 2020 (2020-12-01), XP093054487, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/protein/XP_007962621> [retrieved on 20230614];;LOKTIONOVA N A ET AL: ""Protection of CHO cells by mutant forms of O^6-alkylguanine-DNA alkyltransferase from killing by 1,3-Bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O^6-benzylguanine or O^6-benzyl-8-oxoguanine"", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 58, no. 2, 15 July 1999 (1999-07-15), pages 237 - 244, XP027209659, ISSN: 0006-2952, [retrieved on 19990715];;MAIER P ET AL: ""Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O6-methylguanine-DNA methyltransferaseP140K"", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 17, no. 3, 29 October 2009 (2009-10-29), pages 389 - 399, XP037773196, ISSN: 0969-7128, [retrieved on 20091029], DOI: 10.1038/GT.2009.133",PENDING
46,US,A1,US 2014/0304603 A1,140-416-406-630-412,2014-10-09,2014,US 201313857330 A,2013-04-05,US 201313857330 A,2013-04-05,FULL FIDELITY REMOTE VIDEO EDITING,"Video editing methods and systems enable an editor to edit a video project for which source media assets are located at a media storage server located remotely from the editor with substantially the same fidelity and editing feature set that would be available if the source media assets and editor were co-located. A video editing client used by the editor maintains a persistent cache of proxy media with the layers of the video project stored independently, facilitating editing with combinations locally originated assets and remote assets. The client requests frames not already cached from the remote server via a low bandwidth network. Unless a frame is purged from the cache, no frame is requested from the server more than once. A multi-level priority prefetching scheme, including sequence-based prefetching, populates the cache with frames likely to be requested during editing.",AVID TECHNOLOGY INC,FORGET ERIC;;CAPRIA FRANCIS A;;DESBOIS DANIEL;;FINCHER THOMAS G;;GRATTON RICHARD;;HARNOIS STEPHANE R;;SWARTZ ALAN;;WEI MIN,AVID TECHNOLOGY INC (2013-04-04),https://lens.org/140-416-406-630-412,Patent Application,yes,5,4,4,4,0,G11B27/031;;G11B27/031;;H04N21/23106;;H04N21/23106;;H04N21/4331;;H04N21/47205;;H04N21/854;;H04N21/854,G06F3/048,715/723,0,0,,,,ACTIVE
47,FR,A1,FR 3045965 A1,152-994-933-670-512,2017-06-23,2017,FR 1562823 A,2015-12-18,FR 1562823 A,2015-12-18,MODULE D'EMISSION LUMINEUSE A CONCENTRATION ET DISPOSITIF LASER UTILISANT UN TEL MODULE,"Selon un aspect, l'invention concerne un dispositif laser comprenant un barreau amplificateur laser solide (20) présentant une bande spectrale d'absorption comprise dans la bande spectrale visible - proche infrarouge et au moins un premier module d'émission lumineuse (10A- 10D) destiné au pompage du barreau amplificateur laser solide. Chaque module d'émission lumineuse comprend un ensemble de diodes électroluminescentes (LED) destinées à émettre un flux lumineux dans une première bande spectrale et un concentrateur de lumière ; le concentrateur de lumière comprend un barreau massif en matériau inorganique fluorescent avec au moins une première surface d'éclairement destinée à recevoir la lumière émise par les LED et une surface émettrice destinée à émettre la lumière de fluorescence vers le barreau amplificateur solide, et dans lequel le rapport entre la surface d'éclairement et la surface émettrice est supérieur à 100.",EFFILUX;;INST D'OPTIQUE GRADUATE SCHOOL;;CENTRE NAT DE LA RECH SCIENT - CNRS;;UNIV PARIS SUD 11;;UNIV PARIS 13,BARBET ADRIEN;;BALEMBOIS FRANCOIS;;PAUL AMANDINE;;BLANCHOT JEAN-PHILIPPE;;GALLINELLI THOMAS;;FORGET SEBASTIEN;;CHENAIS SEBASTIEN;;DRUON FREDERIC;;GEORGES PATRICK,,https://lens.org/152-994-933-670-512,Patent Application,no,2,1,2,2,0,H01S3/0933;;H01S3/094049;;H01S3/0915,H01S3/0915,,1,1,128-565-719-554-865,10.1002/adma.200900489,"YING YANG ET AL: ""The Development of Luminescent Concentrators for Pumping Organic Semiconductor Lasers"", ADVANCED MATERIALS, vol. 21, no. 31, 21 August 2009 (2009-08-21), DE, pages 3205 - 3209, XP055288219, ISSN: 0935-9648, DOI: 10.1002/adma.200900489",INACTIVE
48,US,B2,US 9318150 B2,027-442-849-374-107,2016-04-19,2016,US 201313857330 A,2013-04-05,US 201313857330 A,2013-04-05,Full fidelity remote video editing,"Video editing methods and systems enable an editor to edit a video project for which source media assets are located at a media storage server located remotely from the editor with substantially the same fidelity and editing feature set that would be available if the source media assets and editor were co-located. A video editing client used by the editor maintains a persistent cache of proxy media with the layers of the video project stored independently, facilitating editing with combinations locally originated assets and remote assets. The client requests frames not already cached from the remote server via a low bandwidth network. Unless a frame is purged from the cache, no frame is requested from the server more than once. A multi-level priority prefetching scheme, including sequence-based prefetching, populates the cache with frames likely to be requested during editing.",AVID TECHNOLOGY INC,FORGET ERIC;;CAPRIA FRANCIS A;;DESBOIS DANIEL;;FINCHER THOMAS G;;GRATTON RICHARD;;HARNOIS STEPHANE R;;SWARTZ ALAN;;WEI MIN,AVID TECHNOLOGY INC (2013-04-04),https://lens.org/027-442-849-374-107,Granted Patent,yes,6,2,4,4,0,G11B27/031;;G11B27/031;;H04N21/23106;;H04N21/23106;;H04N21/4331;;H04N21/47205;;H04N21/854;;H04N21/854,G11B27/031;;H04N21/231;;H04N21/854,,1,0,,,"Quantel, QTube, Product Brochure, Feb. 15, 2012, 16 pages.",ACTIVE
49,FR,B1,FR 3045965 B1,133-580-097-439-980,2018-05-11,2018,FR 1562823 A,2015-12-18,FR 1562823 A,2015-12-18,MODULE D'EMISSION LUMINEUSE A CONCENTRATION ET DISPOSITIF LASER UTILISANT UN TEL MODULE,,EFFILUX;;INST DOPTIQUE GRADUATE SCHOOL;;CENTRE NAT RECH SCIENT;;UNIV PARIS SUD 11;;UNIV PARIS 13,BARBET ADRIEN;;BALEMBOIS FRANCOIS;;PAUL AMANDINE;;BLANCHOT JEAN-PHILIPPE;;GALLINELLI THOMAS;;FORGET SEBASTIEN;;CHENAIS SEBASTIEN;;DRUON FREDERIC;;GEORGES PATRICK,,https://lens.org/133-580-097-439-980,Granted Patent,no,0,3,2,2,0,H01S3/0933;;H01S3/094049;;H01S3/0915,H01S3/0915,,0,0,,,,INACTIVE
50,US,A1,US 2016/0225407 A1,065-089-976-456-379,2016-08-04,2016,US 201615093819 A,2016-04-08,US 201615093819 A;;US 201313857330 A,2013-04-05,FULL FIDELITY REMOTE VIDEO EDITING,"Video editing methods and systems enable an editor to edit a video project for which source media assets are located at a media storage server located remotely from the editor with substantially the same fidelity and editing feature set that would be available if the source media assets and editor were co-located. A video editing client used by the editor maintains a persistent cache of proxy media with the layers of the video project stored independently, facilitating editing with combinations locally originated assets and remote assets. The client requests frames not already cached from the remote server via a low bandwidth network. Unless a frame is purged from the cache, no frame is requested from the server more than once. A multi-level priority prefetching scheme, including sequence-based prefetching, populates the cache with frames likely to be requested during editing.",AVID TECH INC,FORGET ERIC;;CAPRIA FRANCIS A;;DESBOIS DANIEL;;FINCHER THOMAS G;;GRATTON RICHARD;;HARNOIS STEPHANE R;;SWARTZ ALAN;;WEI MIN,AVID TECHNOLOGY INC (2013-04-04),https://lens.org/065-089-976-456-379,Patent Application,yes,4,0,4,4,0,G11B27/031;;G11B27/031;;H04N21/23106;;H04N21/23106;;H04N21/4331;;H04N21/47205;;H04N21/854;;H04N21/854,G11B27/031;;H04N21/433;;H04N21/472;;H04N21/854,,0,0,,,,ACTIVE
51,US,B2,US 9633694 B2,014-769-238-021-786,2017-04-25,2017,US 201615093819 A,2016-04-08,US 201615093819 A;;US 201313857330 A,2013-04-05,Full fidelity remote video editing,"Video editing methods and systems enable an editor to edit a video project for which source media assets are located at a media storage server located remotely from the editor with substantially the same fidelity and editing feature set that would be available if the source media assets and editor were co-located. A video editing client used by the editor maintains a persistent cache of proxy media with the layers of the video project stored independently, facilitating editing with combinations locally originated assets and remote assets. The client requests frames not already cached from the remote server via a low bandwidth network. Unless a frame is purged from the cache, no frame is requested from the server more than once. A multi-level priority prefetching scheme, including sequence-based prefetching, populates the cache with frames likely to be requested during editing.",AVID TECH INC,FORGET ERIC;;CAPRIA FRANCIS A;;DESBOIS DANIEL;;FINCHER THOMAS G;;GRATTON RICHARD;;HARNOIS STEPHANE R;;SWARTZ ALAN;;WEI MIN,AVID TECHNOLOGY INC (2013-04-04),https://lens.org/014-769-238-021-786,Granted Patent,yes,7,0,4,4,0,G11B27/031;;G11B27/031;;H04N21/23106;;H04N21/23106;;H04N21/4331;;H04N21/47205;;H04N21/854;;H04N21/854,G11B27/031;;H04N21/231;;H04N21/433;;H04N21/472;;H04N21/854,,1,0,,,"Quantel, QTube, Product Brochure, Feb. 15, 2012, 16 pages.",ACTIVE
52,IL,A,IL 308346 A,144-432-368-366-168,2024-01-01,2024,IL 30834623 A,2023-11-06,US 202163187049 P;;US 202163249809 P;;US 202263317174 P;;US 202263337445 P;;US 2022/0028594 W,2021-05-11,Polo like kinase 4 inhibitors,,ORIC PHARMACEUTICALS INC;;NDUBAKU CHUDI;;MOORE JARED THOMAS;;GIBBONS PAUL ANTHONY;;CHANG JAE HYUK;;ROMERO F ANTHONY;;DU XIAOHUI;;KAWAI HIROYUKI;;CIBLAT STEPHANE;;WANG HONG;;ALBERT VINCENT;;CONSTANTINEAU FORGET LEA;;SILVA HUGO DE ALMEIDA;;POLAT DILAN EMINE;;NAYYAR AMIT;;SHORE DANIEL GORDON MICHAEL;;WU KEJIA;;TAN JOANNE,NDUBAKU CHUDI;;MOORE JARED THOMAS;;GIBBONS PAUL ANTHONY;;CHANG JAE HYUK;;ROMERO F ANTHONY;;DU XIAOHUI;;KAWAI HIROYUKI;;CIBLAT STEPHANE;;WANG HONG;;ALBERT VINCENT;;CONSTANTINEAU-FORGET LEA;;SILVA HUGO DE ALMEIDA;;POLAT DILAN EMINE;;NAYYAR AMIT;;SHORE DANIEL GORDON MICHAEL;;WU KEJIA;;TAN JOANNE,,https://lens.org/144-432-368-366-168,Patent Application,no,0,0,7,7,0,C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D495/04;;C07D498/04;;A61P35/00;;C07D491/107;;C07F9/5325;;C07D491/048;;C07D471/04;;C07D403/14;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;A61K45/06;;C07F9/65583;;C07D498/08;;A61K45/06;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07D498/08;;C07F9/5325;;C07F9/65583;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D413/14,A61K45/06;;A61P35/00,,0,0,,,,PENDING
53,TW,A,TW 202309008 A,186-776-877-029-71X,2023-03-01,2023,TW 111117542 A,2022-05-10,US 202163187049 P;;US 202163249809 P;;US 202263317174 P;;US 202263337445 P,2021-05-11,POLO Like Kinase 4 inhibitors,"Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.",ORIC PHARMACEUTICALS INC,NDUBAKU CHUDI;;MOORE JARED THOMAS;;GIBBONS PAUL ANTHONY;;CHANG JAE HYUK;;ROMERO F ANTHONY;;DU XIAOHUI;;KAWAI HIROYUKI;;CIBLAT STEPHANE;;WANG HONG;;ALBERT VINCENT;;CONSTANTINEAU-FORGET LEA;;SILVA HUGO DE ALMEIDA;;POLAT DILAN EMINE;;NAYYAR AMIT;;SHORE DANIEL GORDON MICHAEL;;WU KE-JIA;;TAN JOANNE,,https://lens.org/186-776-877-029-71X,Patent of Addition,no,0,0,7,7,0,C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D495/04;;C07D498/04;;A61P35/00;;C07D491/107;;C07F9/5325;;C07D491/048;;C07D471/04;;C07D403/14;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;A61K45/06;;C07F9/65583;;C07D498/08;;A61K45/06;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07D498/08;;C07F9/5325;;C07F9/65583;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D413/14,C07D401/14;;A61K31/416;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/5377;;A61K31/5386;;A61K31/553;;A61P35/00;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04,,0,0,,,,PENDING
54,US,A1,US 2023/0365537 A1,168-120-954-865-726,2023-11-16,2023,US 202318308441 A,2023-04-27,US 202318308441 A;;US 2022/0028594 W;;US 202263337445 P;;US 202263317174 P;;US 202163249809 P;;US 202163187049 P,2021-05-11,POLO LIKE KINASE 4 INHIBITORS,"Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.",ORIC PHARMACEUTICALS INC,NDUBAKU CHUDI;;MOORE JARED THOMAS;;GIBBONS PAUL ANTHONY;;CHANG JAE HYUK;;ROMERO F ANTHONY;;DU XIAOHUI;;KAWAI HIROYUKI;;CIBLAT STEPHANE;;WANG HONG;;ALBERT VINCENT;;CONSTANTINEAU-FORGET LEA;;SILVA HUGO DE ALMEIDA;;POLAT DILAN EMINE;;NAYYAR AMIT;;SHORE DANIEL GORDON MICHAEL;;WU KEJIA;;TAN JOANNE,ORIC PHARMACEUTICALS INC (2022-05-22);;PARAZA PHARMA INC (2022-05-30),https://lens.org/168-120-954-865-726,Patent Application,yes,0,0,7,7,0,C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D495/04;;C07D498/04;;A61P35/00;;C07D491/107;;C07F9/5325;;C07D491/048;;C07D471/04;;C07D403/14;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;A61K45/06;;C07F9/65583;;C07D498/08;;A61K45/06;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07D498/08;;C07F9/5325;;C07F9/65583;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D413/14,C07D403/14;;C07D401/14;;C07D403/04;;C07D405/14;;C07D413/14,,0,0,,,,ACTIVE
55,US,B2,US 11858915 B2,110-638-066-891-610,2024-01-02,2024,US 202318308441 A,2023-04-27,US 202318308441 A;;US 2022/0028594 W;;US 202263337445 P;;US 202263317174 P;;US 202163249809 P;;US 202163187049 P,2021-05-11,Polo like kinase 4 inhibitors,"Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.",ORIC PHARMACEUTICALS INC,NDUBAKU CHUDI;;MOORE JARED THOMAS;;GIBBONS PAUL ANTHONY;;CHANG JAE HYUK;;ROMERO F ANTHONY;;DU XIAOHUI;;KAWAI HIROYUKI;;CIBLAT STEPHANE;;WANG HONG;;ALBERT VINCENT;;CONSTANTINEAU-FORGET LEA;;SILVA HUGO DE ALMEIDA;;POLAT DILAN EMINE;;NAYYAR AMIT;;SHORE DANIEL GORDON MICHAEL;;WU KEJIA;;TAN JOANNE,ORIC PHARMACEUTICALS INC (2022-05-22);;PARAZA PHARMA INC (2022-05-30),https://lens.org/110-638-066-891-610,Granted Patent,yes,42,0,7,7,0,C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D495/04;;C07D498/04;;A61P35/00;;C07D491/107;;C07F9/5325;;C07D491/048;;C07D471/04;;C07D403/14;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;A61K45/06;;C07F9/65583;;C07D498/08;;A61K45/06;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07D498/08;;C07F9/5325;;C07F9/65583;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D413/14,C07D403/14;;C07D401/14;;C07D403/04;;C07D405/14;;C07D413/14,,22,19,048-441-450-443-630;;085-389-653-740-025;;080-922-182-392-407;;021-288-990-205-82X;;045-883-460-362-788;;060-802-346-170-56X;;158-630-848-169-337;;036-668-562-080-687;;049-604-187-098-226;;059-280-173-035-691;;036-373-730-261-930;;078-855-200-813-203;;096-598-500-478-96X;;057-193-424-694-248;;023-003-015-464-78X;;009-781-341-887-490;;033-925-317-319-389;;084-244-210-752-891;;025-967-599-494-614,10.1016/j.bmcl.2010.09.112;;20971641;;17125279;;10.1021/jm060897w.s001;;10.1021/jm060897w;;10.1158/1538-7445.sabcs22-p3-07-18;;10.1021/jm400380m;;23829549;;10.1038/s41419-018-1071-2;;pmc6194023;;30337519;;27592744;;10.1016/j.bmcl.2016.08.063;;10.1039/c7ra02518a;;10.1016/j.ccr.2014.05.006;;25043604;;10.1016/j.tetlet.2012.01.120;;24867164;;24867403;;10.1021/jm500537u;;25723005;;10.1021/jm5005336;;10.1021/acsmedchemlett.7b00418.s001;;10.1021/acsmedchemlett.7b00418;;pmc5807868;;29456794;;pmc4777322;;10.1021/acs.jmedchem.5b00710;;26258521;;31303643;;pmc6738068;;10.1038/s41416-019-0517-3;;10.1021/acs.jmedchem.7b00017;;10.1021/acs.jmedchem.7b00017.s002;;28368119;;10.1021/acs.jmedchem.7b00017.s001;;10.1016/j.tips.2015.04.005;;25975227;;10.1016/j.bmc.2015.08.006;;26358279;;pmc6802211;;31628334;;10.1038/s41467-019-12768-4;;10.1016/j.ejmech.2015.03.020;;25791677,"Bencsik et al. Discovery of dihydrothieno- and dihyrofuropyrimidines as potent pant Akt inhibitors. Bioor Med Chem Lett 10:7037-7041 (2010).;;Cescon et al. A phase II study of CFI-400945 in patients with advance/metastatic HER2-negative breast cancer: Canadian Trials Group (CCTG) IND.237. Poser SABCS 2022.;;Fancelli et al. 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile. J Med Chem 49:7247-7251 (2006).;;Ge et al. Pd-Catalyzed α-Arylation of α,α-Difluoroketones with Aryl Bromides and Chlorides. A Route to Difluoromethylarenes. J Am Chem Soc 136:4149-4152 (2014).;;Hilton et al. CCTG IND.239: A Phase 2 Study of Combined CFI-400945 and Durvalumab in Patients with Advanced Triple Negative Breast Cancer (aTNBC). Poster SABCS 2022.;;Laufer et al. The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents. J Med Chem 56:6069-6087 (2013).;;Lei et al. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death and Disease 9:1066 (2018).;;Li et al., Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3′-indolin]-2′- ones as potent PLK4 inhibitors with oral antitumor efficacy. Bioorg Med Chem Lett. 26(19):4625-4630 (2016).;;Liu et al. Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1H-indazol-6-yl)pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer. RSC Advanced 7(44):27737-27746 (2017).;;Mason et al. Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent. Cancer Cell 26:163-176 (2014).;;Moody et al. Copper-catalysed approach to spirocyclic oxindole via a direct C—H, Ar—H functionalization. Tetrahedron Letters 53:1897-1899 (2012).;;PCT/US2022/028594 International Search Report and Written Opinion dated Aug. 5, 2022.;;Sampson et al., The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro [cyclopropane-1,3′[3H]indol]-2′(1′H).ones as orally bioavailable antitumor agents. J Med Chem. 58(1):130-146 (2015).;;Sampson et al. The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent. J Med Chem 58:147-169 (2015).;;Shi et al. Discovery of 3,3′-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. ACS Med Chem Lett 9:94-97 (2018).;;Tan et al. Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem 58:6589-6606 (2015).;;Veitch et al. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. Br J Cancer121(4):318-324 (2019).;;Wang et al. Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem 60:3828-3850 (2017).;;Wu et al., FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36:422-439 (2015).;;Xing et al. Kinase hinge binding scaffolds and their hydrogen bond patterns. Bioorg Med Chem 23:6520-6527 (2015).;;Xu et al. Green oxidation of indoles using halide catalysis. Nat Commun 10(1):4754 (2019).;;Yu et al. Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges. Eur J Med Chem Eur. 95:35e40 (2015) (with Corrigendum).",ACTIVE
56,WO,A1,WO 2022/240876 A1,148-030-839-898-309,2022-11-17,2022,US 2022/0028594 W,2022-05-10,US 202163187049 P;;US 202163249809 P;;US 202263317174 P;;US 202263337445 P,2021-05-11,POLO LIKE KINASE 4 INHIBITORS,"Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Formula (I)",ORIC PHARMACEUTICALS INC,NDUBAKU CHUDI;;MOORE JARED THOMAS;;GIBBONS PAUL ANTHONY;;CHANG JAE HYUK;;ROMERO F ANTHONY;;DU XIAOHUI;;KAWAI HIROYUKI;;CIBLAT STEPHANE;;WANG HONG;;ALBERT VINCENT;;CONSTANTINEAU-FORGET LEA;;SILVA HUGO DE ALMEIDA;;POLAT DILAN EMINE;;NAYYAR AMIT;;SHORE DANIEL GORDON MICHAEL;;WU KEJIA;;TAN JOANNE,,https://lens.org/148-030-839-898-309,Patent Application,yes,2,1,7,7,0,C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D495/04;;C07D498/04;;A61P35/00;;C07D491/107;;C07F9/5325;;C07D491/048;;C07D471/04;;C07D403/14;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;A61K45/06;;C07F9/65583;;C07D498/08;;A61K45/06;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07D498/08;;C07F9/5325;;C07F9/65583;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D413/14,A61K31/416;;A61K31/4162;;A61K31/4355;;A61K31/4427;;A61K31/4439;;A61K31/454;;A61K31/496;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/54;;A61K31/553;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07F9/53,,2,2,059-280-173-035-691;;060-802-346-170-56X,24867164;;24867403;;10.1021/jm500537u;;27592744;;10.1016/j.bmcl.2016.08.063,"PETER B. SAMPSON, YONG LIU, NARENDRA KUMAR PATEL, MIKLOS FEHER, BRYAN FORREST, SZE-WAN LI, LOUISE EDWARDS, RADOSLAW LAUFER, YUNHUI: ""The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3 H ]indol]-2′(1′ H )-ones as Orally Bioavailable Antitumor Agents"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 58, no. 1, 8 January 2015 (2015-01-08), US , pages 130 - 146, XP055363743, ISSN: 0022-2623, DOI: 10.1021/jm500537u;;LI SZE-WAN; LIU YONG; SAMPSON PETER B.; PATEL NARENDRA KUMAR; FORREST BRYAN T.; EDWARDS LOUISE; LAUFER RADOSLAW; FEHER MIKLOS; BAN: ""Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3′-indolin]-2′-ones as potent PLK4 inhibitors with oral antitumor efficacy"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 26, no. 19, 23 August 2016 (2016-08-23), Amsterdam NL , pages 4625 - 4630, XP029718541, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2016.08.063",PENDING
57,AU,A1,AU 2022/272184 A1,097-904-523-776-897,2023-11-30,2023,AU 2022/272184 A,2022-05-10,US 202163187049 P;;US 202163249809 P;;US 202263317174 P;;US 202263337445 P;;US 2022/0028594 W,2021-05-11,POLO LIKE KINASE 4 INHIBITORS,"Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Formula (I)",ORIC PHARMACEUTICALS INC,NDUBAKU CHUDI;;MOORE JARED THOMAS;;GIBBONS PAUL ANTHONY;;CHANG JAE HYUK;;ROMERO F ANTHONY;;DU XIAOHUI;;KAWAI HIROYUKI;;CIBLAT STEPHANE;;WANG HONG;;ALBERT VINCENT;;CONSTANTINEAU-FORGET LEA;;SILVA HUGO DE ALMEIDA;;POLAT DILAN EMINE;;NAYYAR AMIT;;SHORE DANIEL GORDON MICHAEL;;WU KEJIA;;TAN JOANNE,,https://lens.org/097-904-523-776-897,Patent Application,no,0,0,7,7,0,C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D495/04;;C07D498/04;;A61P35/00;;C07D491/107;;C07F9/5325;;C07D491/048;;C07D471/04;;C07D403/14;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;A61K45/06;;C07F9/65583;;C07D498/08;;A61K45/06;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07D498/08;;C07F9/5325;;C07F9/65583;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D413/14,A61K31/416;;A61K31/4162;;A61K31/4355;;A61K31/4427;;A61K31/4439;;A61K31/454;;A61K31/496;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/54;;A61K31/553;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07F9/53,,0,0,,,,PENDING
58,CA,A1,CA 3217983 A1,090-532-785-670-735,2022-11-17,2022,CA 3217983 A,2022-05-10,US 202163187049 P;;US 202163249809 P;;US 202263317174 P;;US 202263337445 P;;US 2022/0028594 W,2021-05-11,POLO LIKE KINASE 4 INHIBITORS,"Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Formula (I)",ORIC PHARMACEUTICALS INC,NDUBAKU CHUDI;;MOORE JARED THOMAS;;GIBBONS PAUL ANTHONY;;CHANG JAE HYUK;;ROMERO F ANTHONY;;DU XIAOHUI;;KAWAI HIROYUKI;;CIBLAT STEPHANE;;WANG HONG;;ALBERT VINCENT;;CONSTANTINEAU-FORGET LEA;;SILVA HUGO DE ALMEIDA;;POLAT DILAN EMINE;;NAYYAR AMIT;;SHORE DANIEL GORDON MICHAEL;;WU KEJIA;;TAN JOANNE,,https://lens.org/090-532-785-670-735,Patent Application,no,0,0,7,7,0,C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D495/04;;C07D498/04;;A61P35/00;;C07D491/107;;C07F9/5325;;C07D491/048;;C07D471/04;;C07D403/14;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;A61K45/06;;C07F9/65583;;C07D498/08;;A61K45/06;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07D498/08;;C07F9/5325;;C07F9/65583;;A61P35/00;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D413/14,A61K31/4355;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/048;;C07D491/107;;C07D495/04;;C07D498/04;;C07F9/53,,0,0,,,,PENDING
